

## **CURRICULUM VITAE**

**Bradley Charles Martin, Pharm.D., Ph.D.**

### **Business Address**

Department of Pharmacy Practice  
University of Arkansas for Medical Sciences (UAMS)  
4301 W Markham St., Slot 522  
Little Rock, AR 72205-7122  
BMARTIN@uams.edu  
(501) 603-1992  
(501) 296-1168 FAX

### **EDUCATION AND TRAINING**

1989 - 1993	<b>Ph.D. Pharmacy Care Administration</b> June 1993 University of Georgia College of Pharmacy Athens, Georgia 30602
1985 - 1989	<b>Doctor of Pharmacy</b> June 1989 University of Illinois College of Pharmacy Chicago, Illinois 60612
1983 - 1985	<b>Engineering and Pre-Pharmacy Curriculum</b> University of Illinois - Chicago Chicago, Illinois 60612

### **ACADEMIC STATUS**

#### **PRESENT RANK**

**Professor**

#### **TENURE STATUS**

**Tenured**

### **ACADEMIC POSITIONS**

August 2006 - Present	<b>Professor</b> <b>Department of Pharmacy Practice</b> <b>UAMS College of Pharmacy</b> <b>Little Rock, AR 72205</b>
-----------------------	---

January 2009 – Present	<b>Research Associate With Out Compensation HSR&amp;D Service, Department of Veterans Affairs Little Rock, AR 72205</b>
January 2007 – Present	<b>Head, Division of Pharmaceutical Evaluation and Policy Department of Pharmacy Practice UAMS College of Pharmacy Little Rock, AR 72205</b>
August 2004 – June 2006	<b>Associate Professor Department of Pharmacy Practice UAMS College of Pharmacy Little Rock, AR 72205</b>
January 2005 – Present	<b>Adjunct Associate Professor, Department of Health Policy and Management UAMS College of Public Health Little Rock, AR 72205</b>
Sept 2004 – Sept 2009	<b>Adjunct Associate Professor, Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens, Georgia 30602</b>
July 1998 - Aug. 2004	<b>Associate Professor Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens, Georgia 30602</b>
July 2000 - Aug. 2004	<b>Director, Pharmacy Care Administration Graduate Program Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens, Georgia 30602</b>
May 1993 - June 1998	<b>Assistant Professor Department of Pharmacy Care Administration College of Pharmacy University of Georgia Athens, Georgia 30602</b>
August 1989 - May 1993	<b>Teaching / Research Assistant</b>

**Department of Pharmacy Care  
Administration  
College of Pharmacy  
University of Georgia  
Athens, Georgia 30602**

Sept. 1987 - Dec. 1987

**Teaching Assistant - Statistics  
Department of Pharmacy Administration  
University of Illinois College of Pharmacy  
Chicago, Illinois 60612**

### **PROFESSIONAL EMPLOYMENT**

June 1991 - July 2003

**Relief Staff Pharmacist  
Various Independent Community Pharmacies  
Athens, Georgia**

January 1991 - May 1993

**Staff Pharmacist  
Gilbert Health Center  
University of Georgia  
Athens, Georgia 30602**

June 1990 - June 1994

**Staff Pharmacist  
Revco D.S, Inc.  
Athens, Georgia 30605**

Dec. 1985 - August 1989

**Staff Pharmacist - Pharmacy Intern  
University of Illinois Hospital  
Chicago, Illinois 60612**

## **RESIDENT INSTRUCTION AND CONTINUING EDUCATION**

### **PROFESSIONAL PHARM.D. INSTRUCTION**

#### **Course Coordinator**

**Evidence Based Medicine. (PHPR 5643) 2 semester hours, undergraduate class.** Co-Course Coordinator with Dr. Jill Johnson, UAMS

##### **Offered:**

1. Fall 2008: Enrollment: 114 undergraduate pharmacy students (11% effort)
2. Fall 2009: Enrollment: 119 undergraduate pharmacy students (15% effort)
3. Fall 2010: Enrollment: 110 undergraduate pharmacy students (15% effort)
4. Fall 2011: Enrollment: 117 undergraduate pharmacy students (25% effort)

**Pharmacy Statistics. (PHRM3210) 1 semester hour, undergraduate class.**  
University of Georgia

##### **Offered:**

1. Spring 2000: Enrollment: 94 undergraduate pharmacy students (100% effort)
2. Spring 2001: Enrollment: 106 undergraduate pharmacy students (100% effort)
3. Spring 2002: Enrollment: 113 undergraduate pharmacy students (100% effort)
4. Spring 2003: Enrollment: 121 undergraduate pharmacy students (100% effort)

**Pharmaceutical Calculations. (PHM-320 / PHRM3200), 3 semester hour, undergraduate class.** University of Georgia

##### **Offered:**

1. Spring 1997: Enrollment: 112 undergraduate pharmacy students (33% effort)
2. Spring 1998: Enrollment: 97 undergraduate pharmacy students (33% effort)
3. Spring 1999: Enrollment: 104 undergraduate pharmacy students (33% effort)

**Administrative Pharmacy I. (PHM-362), 3 semester hour, undergraduate class.**  
University of Georgia

Offered:

1. Fall 1995: Enrollment: 106 undergraduate pharmacy students  
(67% effort)

**Pharmacy Finance. (PHR-393), 3 quarter hour, undergraduate class**  
University of Georgia.

Offered:

1. Spring 1994: Enrollment: 105 undergraduate pharmacy students  
(100% Effort)
5. Spring 1995: Enrollment: 98 undergraduate pharmacy students  
(100% Effort)

**Undergraduate Research (PHR-598/PHRM5980), An elective 1-5 hour**  
**undergraduate research elective.** University of Georgia / UAMS

<u>Offered:</u>	<u>Students</u>
1. Wntr 1993:	2
2. Fall 1994:	4
3. Fall 1995:	2
4. Wntr 1995:	2
5. Spr 2001:	1
6. Spr 2002:	2
7. Spr 2004:	1

**Undergraduate Research (PHR-521), An elective 1-5 hour undergraduate**  
**special topics elective.** University of Georgia

<u>Offered:</u>	<u>Students</u>
1. Fall 1996:	1

**Course Instructor**

**Pharmacy Management. (PhPr 5733) 3 semester hours, undergraduate class.**  
UAMS

Offered:

6. Spring 2005: Enrollment: 65 undergraduate pharmacy students  
(11% effort)
7. Spring 2007: Enrollment: ~75 undergraduate pharmacy students  
(11% effort)
8. Spring 2008: Enrollment: ~90 undergraduate pharmacy students  
(11% effort)

**Pharmacy Care Management. (PHM-565 / PHRM5650), 2-3 semester hour, undergraduate class.** University of Georgia

Offered:

1. Spring 1997: Enrollment: 101 undergraduate pharmacy students (12% effort)
2. Spring 1998: Enrollment: 105 undergraduate pharmacy students (12% effort)
3. Spring 1999: Enrollment: 104 undergraduate pharmacy students (20% effort)
4. Fall 2000: Enrollment: 101 undergraduate pharmacy students (47% effort)
5. Fall 2001: Enrollment: 95 undergraduate pharmacy students (33% effort)
6. Spring 2003: Enrollment: 115 undergraduate pharmacy students (24% effort)
7. Spring 2004: Enrollment: 120 undergraduate pharmacy students (24% effort)

**Pharmacy and Health Care Systems. (PHRM3750), 3 semester hour, undergraduate class.** University of Georgia

Offered:

1. Spring 1999: Enrollment: 104 undergraduate pharmacy students (8% effort)
2. Spring 2001: Enrollment: 105 undergraduate pharmacy students (10% effort)
3. Spring 2002: Enrollment: 113 undergraduate pharmacy students (5% effort)

**Problem-Based Learning. (PHRM-5140), 1 credit hour, semester, undergraduate course.** University of Georgia

Offered:

1. Fall 1998: Facilitator - Enrollment: 8 undergraduate pharmacy students (100% Effort)
2. Fall 1999: Facilitator - Enrollment: 8 undergraduate pharmacy students (100% Effort)

**Entrepreneurship (PHR-560), An elective 3 credit hour undergraduate class.** Elective, University of Georgia

This course provided pharmacy students with the financial, legal, and management tools necessary to start and maintain a profitable pharmacy business.

Offered:

1. Fall 1992: Enrollment: 12 undergraduate pharmacy students

(30% effort)

## GRADUATE DIDACTIC INSTRUCTION

### Course Coordinator

#### **Applied Research Methods using Retrospective Data Sources (PHSC5343) A required 3 semester hour graduate class. UAMS**

##### Offered:

1. Spring 2008: Enrollment: 4 Pharmaceutical Sciences students (100% effort)
2. Spring 2010: Enrollment: 4 Pharmaceutical Sciences students, 2 Ph.D. students in Health Policy Management (100% effort)

#### **Pharmacoeconomics and Health Care Technology Assessment (PHSC 5353) A required 3 semester hour graduate class. UAMS**

##### Offered:

1. Spring 2007: Enrollment: 5 Pharmaceutical Sciences students (100% effort)
2. Spring 2009: Enrollment: 4 Pharmaceutical Sciences students (100% effort)
3. Spring 2011: Enrollment: 5 Pharmaceutical Sciences students, 3 Health Policy Management Students (100% effort)

#### **Foundations of Pharmaceutical Evaluation and Policy Research Methods (PHSC 5323), A required 3 semester hour graduate class. UAMS**

##### Offered:

1. Fall 2005: Enrollment: 3 Pharmaceutical Sciences students (60% effort)
2. Fall 2006: Enrollment: 3 Pharmaceutical Sciences students (60% effort)
3. Fall 2007: Enrollment: 3 Pharmaceutical Sciences students (60% effort)
4. Fall 2008: Enrollment: 2 Pharmaceutical Sciences students (60% effort)
5. Fall 2009: Enrollment: 2 Pharmaceutical Sciences students (60% effort)
6. Fall 2011: Enrollment: 5 Pharmaceutical Sciences students (50% effort)

**Special Problems In Pharmaceutical Sciences (PHSC 532X)**, A required 1 semester hour graduate class. UAMS.

Offered:

1. Fall 2005 – 1 semester hour: “Journal Club on Pharmaceutical Policy Analysis with a Focus on Medicaid” Enrollment: 3 Pharmaceutical Sciences students (100% effort)
2. Spring 2006 – 2 semester hours: “SAS and Retrospective Database analyses” Enrollment: 3 Pharmaceutical Sciences MS students (100% Effort)

**Pharmaceutical Science Graduate Seminar (PHSC 5041)**, A required 1 semester hour graduate class. UAMS.

Offered:

1. Fall 2005
2. Spring 2006
3. Spring 2008
4. Spring 2010

**Pharmacoeconomics and Health Care Technology Assessment (PHRM-8670)**, A required 3 semester hour graduate class. University of Georgia

Offered:

1. Spring 2000: Enrollment: 13 PCA students (100% effort)
2. Spring 2002: Enrollment: 4 PCA students (100% effort)
3. Spring 2004: Enrollment: 3PCA students (100% effort)

**Research Methods in Pharmacy Care Administration (PHRM-8640)**, A required 3 semester hour graduate class. University of Georgia

Offered:

1. Fall 1999: Enrollment: 8 PCA students (50% effort).
2. Fall 2001: Enrollment: 6 PCA - CET students (33% effort)
3. Fall 2003: Enrollment: 4 PCA - CET students

**Pharmacoepidemiology / Pharmacoeconomics (PHR-862)**, A required 4 quarter hour graduate class. University of Georgia

Offered:

1. Fall 1996: Enrollment: 4 PCA students (50% effort)



**Health Care Systems (PHRM-8630), A required 3 semester hour graduate class.** University of Georgia

Offered:

1. Spring 1999: Enrollment: 8 PCA students (16% effort)
2. Spring 2001: Enrollment: 7 PCA students (10% effort)

**Health Care Systems (PHR-861), A required 4 quarter hour graduate class.** University of Georgia

Offered:

1. Fall 1993: Enrollment: 12 students: 7 M.S. HPB students, 4 MBA students, 1 Ph.D. PCA student and 1 M.S. PCA (100% effort)
2. Fall 1994: Enrollment: 15 students: 9 M.S. HPB students, 4 MBA students, 2 M.S. PCA students (100% effort)
3. Fall 1995: Enrollment: 18 students: 13 M.S. HPB students, 4 PCA students, 1 MBA student (100% effort)
4. Fall 1996: Enrollment: 11 students: 9 M.S. HPB students, 1 PCA student, 1 MBA student (100% effort)
5. Fall 1997: Enrollment: 14 students: 7 M.S. HPB students, 1 Ph.D. HPB student, 3 PCA students, 2 MBA students, 1 Law student. One student already earned a Ph.D. in Psychology (100% effort)

**Pharmacy Care Administration Seminar (PHRM-8620), A required 1 semester credit hour graduate seminar.** University of Georgia

Offered:

1. Fall 99: "Analysis of NHDS, NHAMCS, NAMCS, HCUP, MEPS data" Enrollment: 12 PCA students (100% Effort)
2. Fall 01: "What underlies Medicaid and Medicare Claims Data?" Enrollment: 14 PCA students (100% Effort)
3. Fall 02: "Pharmacoepidemiology" Enrollment: 10 PCA students
4. Fall 03: "Graduate Student Research - Seminars offered by Dr. Martin on propensity scoring and research budgets" Enrollment: 8 PCA students

**Pharmacy Seminar (PHR-803/PHM-803), A required 1 credit hour graduate seminar.** University of Georgia

Offered:

1. Winter 94: "Journal Club" Enrollment: 5 PCA students (100% Effort)
2. Winter 95: "Measuring Health Related Quality of Life" Enrollment: 7 PCA students (100% Effort)

3. Winter 96: "Analysis of the National Hospital Discharge Survey and the National Health Interview Survey" Enrollment 6 PCA students (100% Effort)
4. Spring 97: "Baseline Statistics of a Women's Epidemiologic Health Data Base" Enrollment 6 PCA students (100% Effort)
5. Spring 98: "The Medical Outcomes Trust Guidelines on Assessing Quality of Life" Enrollment 8 PCA Students (100% Effort)

**Special Problems in Health Promotion and Behavior (HPB-600), An elective 1 credit hour graduate class.** University of Georgia

<u>Offered:</u>	<u>Students</u>
1. Fall 1993:	4 M.S. HPB students
2. Fall 1994:	4 M.S. HPB students
3. Fall 1995:	5 M.S. HPB students
4. Fall 1996:	4 M.S. HPB students
5. Fall 1997:	2 M.S. HPB students

**Masters Research (PHR-700M), An elective 1-10 hour Masters student research course.** University of Georgia

Offered: As needed for graduate student supervision.

**Doctoral Research (PHR-900D), An elective 1-10 hour Doctoral research course.** University of Georgia

Offered: Continuously from 1994 to present for 1 to 6 students per semester

**Doctoral Dissertation Research (PHR-930D), An elective 1-15 hour Doctoral research course.** University of Georgia

Offered: Continuously from 1995 to present for 1 to 4 students per semester

## PH.D. STUDENTS - MAJOR PROFESSOR

1. **Jean-Francois Ricci** **Ph.D. conferred December 2000** - *Improving Risk Adjustment with Drug Exposure in Administrative Data.*
2. **Ron Cantrell** **Ph.D. Conferred May 2004** - *Development and Validation of Risk Assessment Models to Predict Pharmacy Expenditures for both Commercial and Medicaid Populations.*  
Recipient of The Managed Care Pharmacy Fellowship: Sponsored by Athens Area Health Plan Select; 1998-00, Recipient of a University Wide Assistantship, 2001-2002.
3. **Sandhya Pannicker** **Ph.D. Conferred December 2004** - *Impact of Anti-Allergic Medication on Asthma Incidence Cost and Exploratory Analysis of for Risk Factors for Asthma.*  
Recipient of an Internship sponsored by GlaxoSmithKline 2000. Recipient of The Managed Care Pharmacy Fellowship: Sponsored by Athens Area Health Plan Select; 2001.
4. **Rahul Ganguly** **Ph.D. Conferred May 2003** - *Antipsychotic Polypharmacy vs. Monotherapy in the Treatment of Schizophrenia.*  
Nominated to Represent the University of Georgia in the 2003 Council of Graduate Schools (CGS) / UMI Distinguished Dissertation Award Competition in Biological and Life Sciences (Peer reviewed nomination where only best at UGA is forwarded to national competition)
5. **Dayin Koompalum** **Ph.D. Conferred August 2004** - *The Risk Benefit Profile of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) as Chemopreventives.*  
Recipient of a Thailand Government Sponsored Fellowship and was awarded a scholarship to attend the 1<sup>st</sup> International Conference on Therapeutic Risk Management & 19<sup>th</sup> International Conference on Pharmacoepidemiology
6. **Hua Chen** **Ph.D. Conferred August 2005** - *The economic and clinical impacts of prescribing antidepressant, anticonvulsant and antipsychotic medications off-label for patients with anxiety, depression, bipolar disorder or schizophrenia*  
Recipient of a University Wide Assistantship 2000 - 2003. GlaxoSmithKline Summer Internship 2004

7. **Anand Shewale** **Ph.D. conferred December 2016** - *Comparative effectiveness of Hyaluronic acid injections for delay of surgical interventions among patients with knee osteoarthritis*  
Recipient of the ACHI Health Policy Fellowship 2014-2015
8. **Anuj Shah** Anticipated graduation Fall 2017  
Recipient of the ACHI Health Policy Fellowship 2016-2017
9. **Corey Hayes** Anticipated graduation Summer 2018  
Recipient of the 2107 AFPE Fellowship

#### **PH.D. STUDENT DISSERTATIONS ADVISORY COMMITTEE**

1. **Joey Crosby** **Ph.D. received Spring 1995; Dissertation Title - A Bi Phasic Analysis of Medicaid Emergency Room Utilization about a Prescription Drug Constraint. Committee member**
2. **Raul Arocho** **Ph.D. received Spring 1995; Dissertation Title Validation of the USA-Spanish Version of the SF-36 in the Cuban American Population. Committee member**
3. **Christopher Cook** **Ph.D. received Spring 2002; Dissertation Title Validation of the Transtheoretical Model in Medication Compliance Behavior. Committee member**
4. **Melanie Provost** **Ph.D. received Summer 2004; Dissertation Title – The Impact of E-health Information on Patient Medication Adherence, Attitudes, and Knowledge.**

#### **M.S. STUDENT - MAJOR PROFESSOR**

1. **Paul Anderson**
2. **Kayleigh Majercak** **M.S. conferred Fall 2014;**  
*Use Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) And Risks Of Breast And Endometrial Cancer Among Postmenopausal Women: A Plco Study*

3. **Josh Brown** **M.S. conferred Fall 2014;**  
*Comparison of inappropriate prescribing criteria for the elderly – Beers 2003, Beers 2012, and STOPP Criteria*
4. **Anand Shewale** **M.S. conferred Summer 2014;**  
*Comparison Of Atrial Fibrillation Decision Support Tools And Guidelines Used To Guide Anticoagulation Therapy For Patients With Nonvalvular Atrial Fibrillation*
5. **Mir Ali** **M.S. conferred Summer 2014**  
*The Use of Montelukast and Neuropsychiatric Events among Pediatrics with Asthma: A Nested Case-Control Study*
6. **Pravin Patil** **M.S. conferred Spring 2013**  
*A Descriptive Study Of Opioid Use In The Management Of Diabetic Peripheral Neuropathy (DPN) In A Large Commercially Insured Population*
7. **Mugdha Gokhale** **M.S. conferred Summer 2011;**  
*Prescription Acquired Acetaminophen Use and Risk Hepatotoxicity, Nephrotoxicity and Asthma: A Case Control Study*
8. **Kejal Parikh** **M.S. conferred Fall 2008;**  
*Impact of an Inhaled Corticosteroid Preferred Drug List Policy on Utilization, Costs, Adherence, and Persistence in Arkansas Medicaid Enrollees*
9. **Sudeep Karve** **M.S. conferred Summer 2007;**  
*Comparing the Predictive Validity of 8 Adherence Measures Using Administrative Data*
10. **Robert C. Conrad** **M.S. conferred Summer 2007; Thesis Title –**  
*Impact of 3-tier Prescription Copayment Implementation on Prescription Discontinuation and Switching Behavior of Military Beneficiaries. Inflammatory Drug Exposure and the Association with*
11. **Tim Niecko** **M.S. conferred Fall 2001;**  
*A Pharmacoepidemiologic Assessment of Nonsteroidal Anti Inflammatory Drug Exposure and the Association with Colorectal Cancer, Gastrointestinal and Renal Adverse*

*Events*

Recipient of the S.O.S. Summer Internship, 1998

12. **Jayanti Nerurkar** **M.S. conferred Fall 2001; Thesis Title - *Costs Per Death Averted with Venous Thromboembolism Prophylaxis in Patients Undergoing Knee Arthroplasty/Replacement***

## M.S. STUDENT THESES ADVISORY COMMITTEE

1. **Pravin Potukuchi** **M.S. Conferred Summer 2014**
2. **Sharvari Bhurke** **M.S. Conferred Fall 2011; *The Effect of Interaction Between Clopidogrel and Proton Pump Inhibitors on Adverse Cardiovascular Outcomes in Patients with Acute Coronary Syndrome***
3. **Amol Dahamne** **M.S. Conferred Fall 2009; *Metabolic Monitoring of Patients Prescribed Second Generation Antipsychotics***
4. **Prathamesh Pathak** **M.S. Conferred Summer 2007; Thesis Title - *An Investigation of Evidence-Based Versus Non Evidence-Based Off-Label Use of Atypical Antipsychotics in Arkansas Medicaid Pediatric Population: 2001-2005***
5. **Reshma Banavali** **Masters Thesis Defended Spring 2001; Thesis Title - *The Influence of Direct to Consumer Advertising on physician Visit Rates.***
6. **Vijay Nadipelli** **Masters Thesis Defended Summer 1995; Thesis Title – *Job Satisfaction of Community Pharmacy Technicians.***
7. **Anu A Krishnan** University of North Carolina, College of Pharmacy; **Ex-officio committee member**

## POST GRADUATE CONTINUING EDUCATION

1. Martin BC, "Management of Osteoporosis: Issues relating to compliance, survival and costs," a 1.0 hour of ACPE approved presentation to the Savannah Pharmacy Association, Savannah, GA, January 21, 1999.
2. Martin BC, "Overview of Research Design and Statistical Issues Surrounding Clinical and Pharmacoeconomic Investigations," a 1.5 hour ACPE approved presentation to the Georgia Society of Health System Pharmacists, Annual Meeting, Atlanta, GA, October 5, 1996.
3. Martin BC, "Health Care Reform 1995 and the Impact of Managed Care: Potential Implications for Pharmacists," a 1 hour ACPE approved presentation to the R.C. Wilson Pharmaceutical Association, Athens, GA, September 20, 1995.

4. Martin BC, "Financial Analysis of Implementing Pharmaceutical Care in Community Pharmacies, " presented as part of the ACPE approved University of Georgia College of Pharmacy Annual Fall Seminar, Athens, GA, October 9, 1994.
5. Martin BC, Kotzan JA, "Documenting Pharmacist Interventions in Community Pharmacy: Experience with Voice Mail," an ACPE approved presentation at the General Session of the 1994 Georgia Pharmacy Association Annual Meeting. Hilton Head, South Carolina, June 21, 1994.
6. Martin BC, "Health Care Reform 1994: Potential Implications for Pharmacists," a 1 hour ACPE approved presentation to the Gwinette Pharmacy Association, Lawrenceville, GA, March 17, 1994.
7. Martin BC, "Compliance Improvement Techniques - Implementing a Research Protocol" a 1 hour ACPE approved presentation to a group of local pharmacists participating in the West Co. study, Athens, GA, May 26, and May 27, 1993.

## **VISITING AND GUEST LECTURES**

### **International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Short Course**

2007 - 2016	“Instrumental Variables in Addressing Selection Bias in Observational Studies” Instructor with Benjamin Craig, Ph.D., and Antoine Elkhoury, Ph.D.
2012 - 2016	“Introduction to Retrospective Database Analysis”

### **Purdue ISPOR Student Chapter**

February 7, 2008	“Academic Careers”
------------------	--------------------

### **PhPr3423 Pharmacy Practice I**

Fall 2007	Faculty Mentor
-----------	----------------

### **PhPr 5442 Introduction to Research Methods**

Fall 2007	“2 hour lecture on Research Design”
Fall 2006	“2 hour lecture on Research Design”

**Health Services Research and Health Economics Program** (sponsored by the Kerr White Institute and Medical College of Georgia)



December 6, 1999 "Introduction to Principles of Pharmacoeconomics"  
December 6, 1999 "Tools Used to Conduct Pharmacoeconomics"

February 12, 2002 "Introduction to Principles of Pharmacoeconomics"  
February 12, 2002 "Tools Used to Conduct Pharmacoeconomics"

### **Health Care Systems (PHR-593)**

Winter 1994: Provided two one hour lectures entitled "Health Care Reform 1994: Implications for Pharmacist"

Winter 1993: Provided two one hour lectures entitled "Economic Theory of Health Insurance"

### **Research Methods in Pharmacy Care Administration (PHR-853 / PHRM - 8640)**

Sum 1995: Provided one two hour lecture entitled "Documenting Your Data and Preparing it for Analysis"

Sum 1997: Provided two, two hour lectures entitled: "Introduction to Survival Analysis"

Sum 1999: Provided two, two hour lectures entitled: "Documenting Your Data and Preparing it for Analysis" and "Introduction to Survival Analysis"

### **Issues in Health Consumerism and Self-Care (HPB-321)**

Winter 1997: Provided one hour lecture entitled "Providing Health Care: A Primer Covering the A,B,Cs of Health Insurance and Managed Care"

Spring 1998: Provided one hour lecture entitled "Providing Health Care: A Primer Covering the A,B,Cs of Health Insurance and Managed Care"

### **Pharmacy Law / Ethics (PHM-568 / PHRM-5680)**

Fall 1997 - 2004: Provided two one hour lectures entitled "Finance and Ethics: A case study of PharMor"

### **Career Orientation & Communication (PhPr3422)**

Fall 2008-2010: Small Group Facilitator and Mentor for 4 Pharm.D. students

## **SCHOLARLY ACTIVITIES**

### **CHAPTERS IN BOOKS**

1. Fischbach L and **Martin BC** (2014). Cohort and Case Control Studies in Principles of Research Design and Drug Literature Evaluation. ed. Aparasu RR, Sherer JT, Bentley JP. Jones & Bartlett. Burlington, MA
2. **Martin BC** (2011). Secondary Data Analysis: Administrative Data in Research Methods for Pharmaceutical Practice and Policy. ed. Rajender R. Aparasu. Pharmaceutical Press, London, UK: 203-226.
3. **Martin BC** et al. (2010) An abridged Checklist for Evaluation of Research from Retrospective Databases in Analysis of Observational Health-Care Data Using SAS, ed. Douglas Fairies. SAS Institute, Cary, NC. 287-294.
4. **Martin BC**, Pathak DS, Kwon JW, Batenhorst AS, Sharfman M. (2003) “Assessment of the responsiveness of the Migraine-Specific Quality of Life Questionnaire (version 2.1)” in Reducing the Burden of Headache, eds. Olesen J, Steiner TJ, Lipton RB. Oxford University Press Inc, New York, USA: 116-120.
5. **Martin BC**, Pritchard FL, Kotzan JA, Perri M, Sclar DA. (1999) "Case Studies in Pharmacoeconomics and Assessment of Outcomes" in Pharmacoeconomics and Outcome Assessment - A Global Issue ed. Sam Salek, Euromed Communications Ltd. Haslemere, Surrey, England: 53-72.

### **REFEREED ORIGINAL RESEARCH JOURNAL PUBLICATIONS**

(all have undergone significant editorial review)

\*denotes articles in which I was the senior corresponding author and/or the faculty supervisor for graduate student research

1. Hudson TJ, Painter JT, Gressler LE, Lu L, Williams JS, Booth BM, **Martin BC**, Sullivan MD, Edlund MJ. Factors Associated with Opioid Initiation in OEF/OIF/OND Veterans with Traumatic Brain Injury. Pain Med. 2017 PubMed PMID: 29036680.
2. \*Shah A, Hayes CJ, **Martin BC**. (2017) Characteristics of the Initial Opioid Prescription Episode and the Likelihood of Long-Term Opioid Use among Opioid-Naïve Patients — United States, 2006–2015. MMWR. 66(10);265–269. PMID: 28301454
3. \*Shah A, Hayes CJ, **Martin BC**. Factors Influencing Long-Term Opioid Use Among Opioid Naïve Patients: an Examination Of Initial Prescription Characteristics and Pain Etiologies. The Journal of Pain, 18 (11), 1374-1383. PMID: 28711636

4. LE Gressler, **BC Martin**, TJ Hudson, JT Painter. The relationship between concomitant benzodiazepine-opioid use and adverse outcomes among US veterans. Pain. In Press. PMID: 29189516
5. Heldenbrand SD, Dayer LE, **Martin BC**, O'Brien , Choi AN, Gubbins PO, Hawthorne J, Ramey M, Willis L, Flowers SK. Advanced Pharmacy Practice Experience Evaluation Scores are Positively Associated with Multiple-Mini Interview Score, Pre-pharmacy GPA and Pharmacy GPA. American Journal of Pharmaceutical Education, In Press
6. \*Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, Painter JT, **Martin BC**. (2017) Comparative effectiveness of intra-articular hyaluronic acid and corticosteroid injections on the time to surgical knee procedures. J Arthroplasty. 32 (12), 3591-3597. PMID: 28781020
7. \*Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, Painter JT, **Martin BC**. Comparative effectiveness of low, moderate and high molecular weight hyaluronic acid injections in delaying time to knee surgery. J Arthroplasty. In Press. PMID: 28606459
8. Dayer LE, Shilling R, Van Valkenburg M, **Martin BC**, Gubbins PO, Hadden K, Heldenbrand S. (2017) Assessing the Medication Adherence App Marketplace From the Health Professional and Consumer Vantage Points. JMIR mHealth and uHealth 5 (4), e45. PMID: 28428169
9. Hudson TJ, Painter JT, **Martin BC**, Austen MA, Williams JS, Fortney J, Sullivan MD, Edlund MJ. (2017) Pharmacoepidemiologic analyses of opioid use among OEF/OIF/OND veterans. Pain. 2017. PubMed PMID: 28195856.
10. Casciano B, Krishnan J, Small MB, Li C, Dotiwala Z, **Martin BC**. (2017) Progression to Uncontrolled Severe Asthma: A novel risk equation. J Manag Care Pharm. 2017; 23(1):44-50. PubMed PMID: 28025923.
11. Painter JT, **Martin BC**, Li C, Bodhani A, Pyne JM (2017) Genetic Testing for CYP-2D6 Polymorphism Prior to Selective Serotonin Reuptake Inhibitor Prescribing: Results from a Decision Analysis Model. J Psychiatry Cogn Behav: JPCB-123.
12. \* Hammond DA, Kathe N, Shah A, **Martin BC**. Cost-Effectiveness of Histamine(2) Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients. Pharmacotherapy. 2017 Jan;37(1):43-53. PubMed PMID: 27809338.
13. \*Shah A, Shewale A, Hayes CJ, **Martin BC**. (2016) Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke; 2016; 47 (6): 1555-1561: PMID: 27103018.
14. Dayer L, Harrington S, **Martin BC**. Adherence to Adjuvant Neuropathic Pain Medications in a Palliative Care Clinic. J Palliat Med. 2016;19(5):538-41. PubMed PMID: 26835743.
15. Heldenbrand S, **Martin BC**, Gubbins PO, Hadden K, Renna C, Shilling R, Dayer L. (2016) Assessment of Medication Adherence Apps' Features, Functionality, Health Literacy Level

and the Creation of a Searchable Web-based Adherence App Resource for Health Care Professionals and Patients. J Am Pharm Assoc. 2016;56(3):293-302. PMID: 27067551

16. Heldenbrand S, Flowers SK, Bordelon BJ, Gubbins PO, O'Brien C, Stowe CD, **Martin BC.** (2016) Multiple Mini-Interview Performance Predicts Academic Difficulty in the Pharm.D. Curriculum. Am J Pharm Education. 2016 Mar 25;80(2):27: PMID: 27073280
17. \*Brown JD, Hutchison LC, Li C, Painter JT, **Martin BC.** (2016) Predictive Validity of the Beers and Screening Tool of Older Persons Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States. J Am Geriatr Soc. 2016;64(1):22-30: PMID: 26782849
18. \*Shewale AR, Johnson JT, Li C, Nelsen D, **Martin BC.** (2015) Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis. 2015;24(12): 2845-53: PMID: 26482369
19. \*Hayes CJ, Hudson TJ, Phillips MM, Bursac Z, Williams JS, Austin MA, Edlund MJ, **Martin BC.** (2015) The influence of propoxyphene withdrawal on opioid use in veterans. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1180-8. PMID: 26248742.
20. \*Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC.** (2015) Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation. Healthcare. 2015; 3(1):130-145.
21. \*Ali MM, O'Brien CE, Cleves MA, **Martin BC.** (2015) Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study. Pharmacoepidemiology and Drug Safety. 2015; 24(4):435-45. PMID: 25683909.
22. \*Patil PR, Wolfe J, Said Q, Thomas J, **Martin BC.** (2015) Opioid Use in the Management of Diabetic Peripheral Neuropathy (DPN) in a Large Commercially Insured Population. The Clinical Journal of Pain. 2015 May;31(5):414-24. PubMed PMID: 25853725
23. **Martin BC,** Shewale A. (2014) Validity of Electronic Prescription Claims Records: A Comparison of Commercial Insurance Claims with Pharmacy Provider Derived Records. Innovations in Pharmacy. 2014;5(4):1-13
24. Vanderlip E, Sullivan M, Edlund M, **Martin BC,** Fortney J, Austen M, Williams JS, Hudson T. (2014) National Study of Discontinuation of Long-Term Opioid Therapy among Veterans. Pain. 2014 Dec; 155(12): 2673-9. PMID: 25277462
25. Edlund MJ, Austen MA, Sullivan MD, **Martin BC,** Williams JS, Fortney JC, Hudson TJ. (2014) Patterns of opioid use for chronic non-cancer pain in the Veterans Health Administration from 2009 to 2011. Pain. 2014 Nov; 155(11): 2337-43. PMID: 25180008.
26. \*Berger ML, **Martin BC,** Husereau D, Worley K, Allen JD, Yang W, Quon NC, Mullins CD, Kahler KH, Crown W. (2014) A questionnaire to assess the relevance and credibility of

- observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014 Mar;17(2):143-56. PubMed PMID: 24636373.
27. Dhamane AD, **Martin BC**, Brixner DI, Hudson TJ, Said Q. (2013) Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract. 2013 Sep;19(5):360-74. PubMed PMID: 24042242.
  28. Casciano JP, Dotiwala ZJ, **Martin BC**, Kwong WJ. (2013) The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013 May;19(4):302-16. PubMed PMID: 23627576.
  29. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, **Martin BC**. (2013) Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc. 2013 Mar-Apr;53(2):172-81. PubMed PMID: 23571625.
  30. Dhamane AD, **Martin BC**, Brixner DI, Hudson TJ, Said Q. (2013) Metabolic monitoring of patients prescribed second generation antipsychotics. Journal of Psychiatric Practice. 2013. Sep;19(5):360-74. PubMed PMID: 24042242.
  31. Li C, **Martin BC**, Cummins DF, Andrews LM, Frech-Tamas F, Yadao AM. (2013) Ambulatory resource utilization and cost for gout in the US. American Journal of Pharmacy Benefits. 2013;5(2):e46-e54.
  32. Casciano JP, Singer DE, Kwong WJ, Fox ES, **Martin BC**. (2012) Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. Am J Cardiovasc Drugs. 2012 Oct 1;12(5):313-23. PubMed PMID: 22920047.
  33. \*Kelkar M, Cleves MA, Foster HR, Hogan WR, James LP, **Martin BC**. (2012) Prescription Acquired Acetaminophen Use and the Risk of Asthma in Adults: A Case Control Study. Annals of Pharmacotherapy. 2012 Dec;46(12):1598-608. PMID:23170033
  34. Bhurke SM, **Martin BC**, Li C, Franks AM, Bursac Z, Said Q. (2012) Effect of the Clopidogrel-Proton Pump Inhibitor Drug Interaction on Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome. Pharmacotherapy. 2012; 32(9):809-18. PubMed PMID: 22744772.
  35. \*Kelkar M, Cleves MA, Foster HR, Hogan WR, James LP, **Martin BC**. (2012) Acute and chronic acetaminophen use and renal disease: a case-control study using pharmacy and medical claims. J Manag Care Pharm. 2012 Apr;18(3):234-46. PMID:22468732
  36. Said Q, **Martin BC**, Joish VN, Kreilick C, Mathai SC. (2012) The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15(3):500-8. PMID:22313330

37. \*Gokhale M, **Martin BC**. (2012) Prescription-acquired acetaminophen use and potential overuse patterns: 2001-2008. Pharmacoepidemiol Drug Saf. 2012 Feb; 21(2):226-30. (Epub ahead of print) PMID:21915939
38. Li C, **Martin BC**. (2011) Trends in emergency department visits attributable to acetaminophen overdoses in the United States: 1993-2007. Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):810-8. PMID: 21796717
39. **Martin BC**, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. (2011) Long-term chronic opioid therapy discontinuation rates from the TROUP Study. J Gen Intern Med. 2011 Dec;26(12):1450-7. PMID: 21751058
40. Richardson LP, Fan MY, McCarty CA, Katon W, Edlund M, DeVries A, **Martin BC**, Sullivan M. (2011) Trends in the prescription of opioids for adolescents with non-cancer pain. Gen Hosp Psychiatry. 2011 Sept-Oct;33(5):423-8. PMID: 21749839
41. Domino ME, **Martin BC**, Wiley-Exley E, Richards S, Henson A, Carey TS, Sleath B. (2011) Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment. Health Serv Res. 2011;46:900-919. PMID:21306363
42. Sleath B, Domino ME, Wiley-Exley E, **Martin BC**, Richards S, Carey T. (2010) Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race. Community Ment Health J. 2010 Jun;46(3):265-72. PMID:20091226
43. Edlund MJ, **Martin BC**, Fan MY, Devries A, Braden JB, Sullivan MD. (2010) Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend. 2010 Nov 1;112(1-2):90-8. PMID: 20634006
44. Braden JB, Russo J, Fan MY, Edlund MJ, **Martin BC**, DeVries A, Sullivan MD. (2010) Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010 Sep 13;170(16):1425-32. PMID: 20837827
45. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, **Martin BC**. (2010) Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: the TROUP Study. Pain. 2010 Aug;150(2):332-9. PMID: 20554392
46. Edlund MJ, **Martin BC**, Devries A, Fan MY, Braden JB, Devries A, Sullivan MD. (2010) An analysis of heavy utilizers of opioids for chronic non-cancer pain in the TROUP study. J Pain Symptom Manage. 2010 Aug;40(2):279-89. PMID: 20579834
47. Edlund MJ, **Martin BC**, Devries A, Fan MY, Braden JB, Sullivan MD. (2010) Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain. 2010 Jan;26(1):1-8. PMID: 20026946

48. Pathak P, Helm ME, **Martin BC**, Henderson C, West D. (2010) Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population: 2001-2005. Psychiatr Serv. 2010 Feb; 61(2):123–9. PMID: 20123816
49. Thielke SM, Simoni-Wastila L, Edlund MJ, DeVries A, **Martin BC**, Braden JB, Fan MY, Sullivan MD. (2010) Age and sex trends in long-term opioid use in two large American health systems between 2000 and 2005. Pain Med. 2010 Feb;11(2):248-56. PMID: 20002323
50. \*Karve S, Cleves MA, Helm M, Hudson TJ, West DS, **Martin BC**. (2009) Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009 Sep;12(6):989-95. PMID: 19402852
51. Johnson ML, Crown W, **Martin BC**, Dormuth CR, Siebert U. (2009) Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part III. Value Health. 2009 Nov-Dec;12(8):1062-73. PMID: 19793071
52. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, **Martin BC**. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009 Sep;25(9):2303-10. PMID: 19635045
53. Cox E, **Martin BC**, Van Staa T, Garbe E, Siebert U, Johnson ML. (2009) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health. 2009 Nov-Dec;12(8):1053-61. PMID: 19744292
54. **Martin BC**, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. (2009) Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009 Jan;43(1):36-44. PMID: 19126828
55. **Martin BC**, Church TS, Bonnell R, Ben-Joseph R, Borgstadt T. (2009) The impact of overweight and obesity on the direct medical costs of truck drivers. J Occup Environ Med. 2009 Feb;51(2):180-4. PMID: 19209039
56. \*Karve S, Cleves MA, Helm M, Hudson TJ, West DS, **Martin BC**. (2008) An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008 Nov;46(11):1125-33. PMID: 18953222
57. Sullivan MD, Edlund MJ, Fan MY, DeVries A, Brennan Braden J, **Martin BC**. (2008) Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008 Aug 31;138(2):440-9. PMID: 18547726

58. Braden JB, Fan MY, Edlund MJ, **Martin BC**, Devries A, Sullivan MD. (2008) Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP Study. J Pain. 2008 Nov;9(11):1026-35. PMID: 18676205
59. \*Chen H, Kennedy WK, Dorfman JH, Finchan JE, Reeves J, **Martin BC**. (2007) The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Curr Med Res Opin. 2007 Jun;23(6):1351-65. PMID: 17559734
60. Gold DT, **Martin BC**, Frytak JR, Amonkar MM, Cosman F. (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007 Mar;23(3):584-94. PMID: 17355739
61. **Martin BC**, Barghout V, Cerulli A. (2006) Direct medical costs of constipation in the United States. Manag Care Interface. 2006 Dec;19(12):43-9. PMID: 17274481
62. \*Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, **Martin BC**. (2006) Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006 Jun;67(6):972-982. PMID: 16848658
63. \*Provost M, Koopalum D, Dong D, **Martin BC** (2006). The initial development of the WebMedQual scale: domain assessment of the construct of quality of health web sites. Int J Med Inform. 2006 Jan;75(1):42-57. PMID: 16169770
64. \*Sapra S, Nielsen K, **Martin BC**. (2005) The net cost of asthma to North Carolina Medicaid and the influence of comorbidities that drive asthma costs. J Asthma. 2005 July-Aug; 42(6):469-77. PMID: 16293542
65. \*Chen H, Deshpande AD, Jiang R, **Martin BC**. (2005) An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid Population. Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):629-38. PMID: 15597329
66. Cook CL, Wade WE, **Martin BC**, Perri M 3rd. (2005). Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc. 2005 Mar-Apr;45(2):151-9. PMID: 15868757
67. Miller LS, **Martin BC**. (2004) Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia. Schizophr Bull. 2004;30(4):983-95. PMID: 15954202
68. \*Ganguly R, Kotzan JA, Miller LS, Kennedy K, **Martin BC**. (2004) Prevalence, trends and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004 Oct;65(10):1377-88. PMID: 15491242
69. **Martin BC**, Ganguly R, Panicker S, Frech F, Barghout V. (2003) Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin. 2003;19(8):771-80. PMID: 14687449



70. \*Ganguly R, Miller LS, **Martin BC**. (2003) Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res. 2003 Sep 1;63(1-2):111-9. PMID: 12892865
71. Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, **Martin BC**, Stang P. (2003) A checklist for retrospective database studies -- report of the ispor task force on retrospective databases. Value Health. 2003 Mar-Apr;6(2):90-97. PMID: 12641858
72. \*Nerurkar J, Wade WE, **Martin BC**. (2002) "Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. Pharmacotherapy. 2002 Aug;22(8):990-1000. Review. PMID: 12173802
73. \*Cantrell R, Young F, **Martin BC**. (2002) Antibiotic prescribing in ambulatory care settings for adults with colds, upper respiratory tract infections, and bronchitis. Clin Ther. 2002 Jan;24(1):170-82. PMID: 11833830
74. Kotzan JA, Maclean R, Wade W, **Martin BC**, Lami H, Tadlock G, Gottlieb M. (2002) Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort. Clin Ther. 2002 Feb;24(2):237-48. PMID: 11911554
75. **Martin BC**, Miller LS, Kotzan JA. (2001) Psychotropic prescription use and costs in the 1990s: current trends and five year time series forecasts. Schizophr Res. 47:281-292.
76. **Martin BC**, Chisholm MA, Kotzan JA. (2001) Isolating the cost of osteoporosis-related fracture for postmenopausal women. A population based study. Gerontology. 2001 Jan-Feb;47(1):21-9. PMID: 11244288
77. Boudinot SG, **Martin BC**. (2001) Online anatomy lab (oal): a self-regulated approach to the instruction of human anatomy. Interactive Multimedia Electronic Journal of Computer Enhanced Learning. 3(1): (<http://imej.wfu.edu/articles/2001/1/01/index.asp>)
78. **Martin BC**, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P. (2000). Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000 Mar;40(3):204-15. PMID: 10759923
79. Gedaly S, **Martin BC**, Arocho R, McMillan CA. (2000). The women pharmacists' health survey: preliminary results from a multi-regional survey of women pharmacists. Southern Journal of Health System Pharmacist. 4(3):5-12
80. **Martin BC**, Ricci JF, Kotzan JA, Lang K, Menzin J. (2000). The net cost of Alzheimer disease and related dementia: a population based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord. 2002 July-Sep;14(3):151-9. PMID: 10994656
81. \*Burgess S, **Martin BC**. (2000). Variations in childhood immunization rates for children aged 19-72 months. Southern Journal of Health System Pharmacists. 4(1):12-20.

82. Kotzan JA, **Martin BC**, Reeves JH, Wade W. (1999). The impact of race and fractures on mortality in a post menopausal Medicaid population. Clin Ther. 1999 Nov;21(11):1988-2000. PMID: 10890268
83. Battle YL, **Martin BC**, Dorfman JH, Miller LS (1999). Seasonality and infectious disease in schizophrenia: the birth hypothesis revisited. J Psychiatr Res. 1999 Nov-Dec;33(6):501-9. PMID: 10628526
84. Wade WE, **Martin BC**, Kotzan JA, Spruill WJ, Chisolm MA, Perri M. (2000). Formulary management of low-molecular-weight-heparins. Pharmacoeconomics. 2000 Jan;17(1):1-12. Review. PMID: 10747761
85. O'Connor CM, Radensky PW, Unger AN, **Martin BC**. (1999) Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. Clin Ther. 1999 Jul;21(7):1254-65. PMID: 10463522
86. \*Ricci JF, **Martin BC**. (1999) Resource Utilization of Ischemic Stroke Patients: A Population Based Study of Georgia Medicaid Recipients. Journal of Research in Pharmaceutical Economics; 9(3): 21-34.
87. Kotzan JA, **Martin BC**, Wade WE. (1999) Persistence with estrogen therapy in a post menopausal Medicaid population. Pharmacotherapy. 1999 Mar;19(3):363-9. PMID: 10221376
88. **Martin BC**, Chisolm MA. (1999) Cross-validation of an instrument measuring pharmacy students attitudes towards pharmaceutical care. American Journal of Pharmaceutical Education. 63(1):46-51.
89. **Martin BC**, Miller LS. (1998) Expenditures for treating schizophrenia: a population-based study of Georgia Medicaid recipients. Schizophr Bull. 1998;24(3):479-88. PMID: 9718639
90. Kotzan JA, **Martin BC**, Poirier S, Nichols GJ, Perri M, Pritchard FL. (1997) Pharmaceutical care: community pharmacist attitudes and practices." The American Journal of Integrated Healthcare, 1(1): 37-42.
91. Chisolm MA, **Martin BC**. (1997) Development of an instrument to measure students attitudes concerning pharmaceutical care. American Journal of Pharmaceutical Education. 61:374-379.
92. Kotzan JA, Perri MP, **Martin BC**. (1996) An assessment of Medicaid prior approval cost containment policies on prescription expenditures: a market share analysis of Medicaid and cash prescriptions. Journal of Managed Care Pharmacy. November/December;2(6):569-574.
93. Miller DW, **Martin BC**, Loo CM. (1996) Sumatriptan and lost productivity: a time series analysis of diary data. Clin Ther. 1996 Nov-Dec;18(6):1263-75. PMID: 9001842

94. \*Misra S, Ricci JF, Gedaly SS, **Martin BC**, Horvath B. (1996) Evaluating health related quality of life in three disease management areas: asthma, diabetes, and hypertension. Journal of Managed Care Pharmacy. 2(4):408-13.
95. **Martin BC**, Perri M 3rd, Kotzan JA. (1996) Health care triage alternatives and the influence of health insurance, educations, and race. Patient Educ Couns. 1996 Aug;28(3):287-96. PMID: 8852104
96. **Martin BC**, McMillan JA, Kotzan JA. (1996) Bias associated with missing out-of-plan prescription data for Medicaid recipients: the whole truth. The Journal of Research in Pharmaceutical Economics. Quarter 3;7:65-77.
97. **Martin BC**, McMillan JA. (1996) The impact of a more restrictive prescription limit on Medicaid recipients: effects on cost, therapy, and out-of-pocket expenditures. Med Care. 1996 Jul;34(7):686-701. PMID: 8676607
98. Perri M, **Martin BC**, Pritchard FL (1995). Improving medication compliance: a practical intervention. The Journal of Pharmacy Technology. July/August; 11:167-72.
99. **Martin BC**, Dorfman JH, McMillan JA, McMillan CA. (1994) Prevalence of migraine headache and association with sex, age, race, and rural/urban residence: a population-based study of Georgia Medicaid recipients. Clin Ther. 1994 Sep-Oct;16(5):855-72. Discussion 854. PMID: 7859245
100. Jankel CA, McMillan JA, **Martin BC**. (1994) Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. Am J Hosp Pharm. 1994 Mar 1;51(5):661-6. PMID: 8203385
101. Jankel CA, **Martin BC**. (1992) Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm. 1992 Jun;49(6):1430-5. PMID: 1529984
102. Ortmeier BG, Wolfgang AP, and **Martin BC**. (1991) Career commitment, career plans, and perceived stress: a survey of pharmacy students. American Journal of Pharmaceutical Education. 55:138-42.

**PROFESSIONAL JOURNAL ARTICLES, EDITORIALS, COMMENTARIES,  
LETTERS TO THE EDITOR** (¥ denotes invited articles)

103. \* Shewale AR, Fischbach LA, Hammond DA, Martin BC. Letter to the Editor on 'Hyaluronic Acid Injections in Medicare Knee Osteoarthritis Patients Are Associated With Longer Time to Knee Arthroplasty'. J Arthroplasty. 2017 Feb;32(2):696-697.
104. Brown JD, Hutchison LC, **Martin BC**. Commentary: Comparing the Tools to Identify Potentially Inappropriate Medications in the Elderly and Future Research Directions. Gerontology & Geriatrics Research. 2016; 5: 321.

105. **Martin BC**, Hayes C, Austen M, Hudson T. Author Response to “Impact of survival bias on opioid-related outcomes when using death as an exclusion criterion”. Pharmacoepidemiology and Drug Safety 2016; 25: 477–478.
106. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, **Martin BC**. Smartphone medication adherence apps: potential benefits to patients and providers: response to Aungst. J Am Pharm Assoc. 2013;53(4):345. PMID: 23892801
107. Pathak P, West D, **Martin BC**. (2010) Weighing the evidence for pediatric antipsychotic use. Psychiatr Serv. 2010 Mar;61(3):325. PMID: 20194416
108. **Martin BC**. (2005) ISPOR comments on the Medicare Rx Data Elements. ISPOR Connections, June;11(3):14.
109. Ganguly R, **Martin BC**, Dorfman J, Rizzo J. (2004) In search of an unbiased estimate of treatment effect using observational data: a comparison of propensity scoring and Heckman two stage sample selection models. ISPOR Connections: April;10(2):1-3.
110. ISPOR Retrospective Data Base Task Force (Chair: Motherall B; Members: Brooks J, Clark MA, Crown W, Davey P, Hutchins D, **Martin BC**, Stang P) (2001) ISPOR task force on retrospective databases - checklist for retrospective database studies working paper. ISPOR News. August;7(4):4-7.
111. **Martin BC**. (2001) The women pharmacists’ health study: preliminary results from a multi-regional survey of women pharmacists” Georgia Pharmacist Quarterly. Summer;78(3):2-11.
112. \*Niecko T. **Martin BC**. (1999) The health insurance portability act of 1996: the issue of portable health care coverage. Journal of Managed Care Pharmacy. March/April;5(2):81-2.
113. \* Cantrell R, **Martin BC**. (1998) The balanced budget agreement of 1997: children’s health insurance program. Feature Article in The Georgia Pharmacy Journal, March;20(3):24-30.
114. ¥ **Martin BC**, Ricci JF, Misra S, Gedaly SS, Horvath B. (1996) Measuring quality of life: a primer for managed care pharmacists. Journal of Managed Care Pharmacy. July /August;4:415-22.
115. **Martin BC**. (1995) Evaluating health related quality of life. Georgia Pharmacist Quarterly,72(3):2,8.
116. **Martin BC** (1989) Acetaminophen in the news again: current concerns with renal effects. Illinois Pharmacist. 51(7):19-20.

117. **Martin BC.** (1989) Pharmacy Gone Temporary. Feature Article Illinois Pharmacist. 51(11):8-11.

## **PRESS RELEASES AND CONTRIBUTIONS TO PRESS**

Max Blau. STAT forecast: Opioids could kill nearly 500,000 Americans in the next decade. STAT. June 27, 2017. Contributed time series forecasts with Corey J Hayes.

## **PUBLISHED ABSTRACTS AND CONFERENCE PAPERS**

1. Chopra DA, Bhandari NR, Kathe N, Shah AB, Moore G, Li C, Thompson J, **Martin BC.** “Difference in Opioid Utilization between commercially insured and traditional Medicaid for low income adults.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, USA. May 23, 2017. (Value in Health, 20 (5), A229).
2. Shah AB, Goudie A, **Martin BC.** “The Influence Of Expanding Medicaid Through Commercially Obtained Insurance Versus Traditional Medicaid On Inpatient Utilization: A Comparison Of Arkansas And Kentucky.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 22, 2017. (Value in Health, 20 (5), A46).
3. Shah AB, Hayes CJ, **Martin BC.** “Which Pain Etiologies Are Most Likely To Result In Long Term Opioid Use? Results From A Large Nationally Representative Inception Cohort Study?” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 23, 2017. (Value in Health, 20 (5), A212).
4. Shewale AR, Barnes LC, Fischbach LA, Ounpraseuth S, Painter JT, **Martin BC.** “Conflicting Comparative Effectiveness Evidence Of Hyaluronic Acid Using Real World Data Evidence. An Update Using A High Dimensional Propensity Score Matching Approach.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 23, 2017. (Value in Health, 20 (5), A142).
5. Kathe NJ, Bhandari NR, Chopra DA, Moore G, Li C, Goudie A, **Martin BC.** “Contrasting Non-Emergent Care Delivered in Emergency Departments and Urgent Care Centers to Arkansas Medicaid and Private Option Enrollees”. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 22, 2017. (Value in Health, 20 (5), A29).
6. **Martin BC.** Shah A. Initial Opioid Prescribing Characteristics and the Transitions from Acute to Long Term Opioid Use: Findings from Big Data. Podium Presentation at the Addiction Health Services Research, Seattle, Washington, October 14, 2016.

7. Shah AB, Hayes C, **Martin BC**. Choice of First Opioid Prescription and the Transitions from Acute to Long Term Opioid Use—Findings from Big Data. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research European Meeting. Vienna, Austria, October 31, 2016. (*Value in Health* 19 (7), A598)
8. Bhandari N, Kathe N, **Martin BC**. Cost of Healthcare Among Metastatic Lung Cancer Patients Receiving Chemotherapy NR Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research European Meeting. Vienna, Austria, October 31, 2016. (*Value in Health* 19 (7), A624-A625)
9. Hayes CJ, Chopra D, Shah AB, **Martin BC**. Impact of State Mandated Queries of The Prescription Drug Monitoring Programs on Opioid And Non-Opioid Drug Related Adverse Effects: A Difference In Difference Approach (*Value in Health* 19 (7), A622)
10. **Martin BC**, Shah AB, Kathe N, Moore G, Li C, Said Q, Goudie A, Thompson J. Determining The Feasibility of Using a Regression Discontinuity Approach to Compare Emergency Room Utilization Between Medicaid Fee-For-Service And Commercially Obtained Coverage In The ACA Medicaid Expansion Population. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Washington, DC, USA. May 25, 2016. (*Value in Health*, 19 (3), A260).
11. Shah AB, Kathe N, Moore G, Li C, Said Q, Goudie A, Thompson J, **Martin BC**. Determining The Feasibility Of Using A Regression Discontinuity Approach To Compare Inpatient Utilization Between Medicaid Fee For Service And Commercially Obtained Coverage In The Aca Medicaid Expansion Population. A Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Washington, DC, USA. May 25, 2016. (*Value in Health*, 19 (3), A260).
12. Shewale AR, Barnes LC, Fischbach LA, Ounpraseuth S, Painter JT, **Martin BC**. “Characterization of initial treatment strategies used to manage incident knee osteoarthritis.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Washington, DC, USA. May 24, 2016. (*Value in Health*, 19 (3), A238).
13. Kathe N, Hayes C, Shewale A, **Martin BC**. Cost Effectiveness Of Therapies For Castration Resistant Metastatic Prostate Cancer. Society of Medical Decision Making, St. Louis, MO, USA, Oct 18-21, 2015.
14. Shilling R, VanValkenburg M, Renna C, Dayer L, **Martin BC**, Hadden K, Heldenbrand S. There are too many Apps for that: Development of a Website helps Patients and Providers find Quality Medication Adherence Applications. Forthcoming at the American Pharmacist Association Annual Meeting. Baltimore, MD, March 2016
15. Shah AB, Shewale AR, Hayes C, **Martin BC**. Cost effectiveness of dabigatran, apixaban, rivaroxaban, edoxaban and warfarin for ischemic stroke prophylaxis among patients with

atrial fibrillation: us private payer's perspective (Poster PS2-7).Society of Medical Decision Making, St. Louis, MO, USA, Oct 18-21, 2015.

16. Shewale AR, **Martin BC**. Comparative effectiveness of rivaroxaban and standard anticoagulant therapies for prevention of primary venous thromboembolism in patients with major orthopedic surgery. A Poster Presentation at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Philadelphia, PA, USA. May 16-20, 2015. (*Value in Health*, 18(3), A131)
17. Hammond DA, Shah A, **Martin BC**. Cost-effectiveness of H2RAs versus PPIs for stress ulcer prophylaxis in critically ill patients. (Poster number: 370) Society of Critical Care Medicine Annual Congress. Orlando, FL, February 20, 2016. (*Crit Care Med*. 2015 Dec;43(12 Suppl 1):94.) and presented at Arkansas Association of Health System Pharmacists, October 8, 2015, Little Rock, AR.
18. Shewale AR, **Martin BC**. Comparative effectiveness of rivaroxaban and standard anticoagulant therapies for prevention of primary venous thromboembolism in patients with major orthopedic surgery. A Poster Presentation at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Philadelphia, PA, USA. May 16-20, 2015.
19. Dayer L, Harrington S, **Martin BC**. Adherence to adjuvant neuropathic pain medications in palliative care. American College of Clinical Pharmacy Virtual Poster Symposium. May, 2015. (*Pharmacotherapy* 2015; 35 (5): e 66-95.)
20. Brown J, Painter J, Li C, Hutchison L, **Martin BC**. Predictive Validity of Inappropriate Prescribing Criteria for Adverse Drug Events, Hospitalizations, and Emergency Department Visits: A Time-To-Event Comparison of the Beers and Stopp Criteria. Poster presented at the 2014 International ISPOR Meeting in Amsterdam, Netherlands, November 10, 2014. (*Value in Health* 17 (7): A505).
21. Brown J; Painter J; Li C; Hutchison L; **Martin BC**. Adverse Drug Events in the Elderly Occurring in Emergency, Inpatient, and Outpatient Departments in an Administrative Claims Database. Poster presented at the 2014 International ISPOR Meeting in Montreal, Canada, May 31-June 4, 2014. (*Value in Health* 17 (3): A155). Podium presentation at the 2014 Southern Pharmacy Administration Conference in Oklahoma City, OK, June 20-22, 2014.
22. Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC**. Comparison of the guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. A poster presented at the 19th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Montreal, QC, Canada. May 31-June 4, 2014. (*Value in Health*, Vol. 17 (3), A124)
23. Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC**. Comparison of atrial fibrillation decision support tools and guidelines used to guide anticoagulation therapy for patients with Nonvalvular Atrial Fibrillation. A poster presented at the 19th Annual International

Society for Pharmacoeconomics and Outcomes Research Conference, Montreal, QC, Canada. May 31-June 4, 2014. Value in Health Vol. 17, Issue 3, Page A124

24. Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC**. Net clinical benefit of the 2014 AHA/ACC/HRS Guideline used to guide anticoagulation therapy for patients with Nonvalvular Atrial Fibrillation. An abstract accepted for poster presentation at the Southern Pharmacy Administration Conference (SPAC) Oklahoma City, OK, June 20-22, 2014.
25. Potukuchi PK, Johnson JT, **Martin BC**, Hutchison LC, Bursac Z, Said Q. Impact of arthritis and other comorbidities on incidence of urinary incontinence: A case control study. Poster Presented at the 2014 ISPOR 19th Annual International Meeting in Montreal, Canada, June 4, 2014. Value in Health 17 (3): PUK6.
26. Potukuchi PK, **Martin BC**, Johnson JT, Hutchison LC, Bursac Z, Said Q. Treatment patterns of urinary incontinence in the presence of comorbidities. Poster Presented at the 2014 ISPOR 19th Annual International Meeting in Montreal, Canada, June 4, 2014. Value in Health 17 (3): PUK1.
27. Hayes C, Phillips M, **Martin BC**, Bursac Z, Hudson T. The Influence of the Propoxyphene Withdrawal on Opioid Use and Opioid Related Adverse Events in Veterans. Podium Presentation at the 2013 Addiction Health Services Research Conference, Portland, OR, October 25, 2013.
28. Ali M, O'Brien C, Cleves M, **Martin BC**. The Use of Montelukast and Neuropsychiatric Disturbances Among Pediatric Asthmatics: A Nested Case Control Study. Poster Presented at the 2012 European ISPOR Meeting in Berlin, Germany, November 7, 2012. Value in Health 15 (7): A559.
29. **Martin BC**, Fan MY, Edlund MJ, Richardson LP, Russo JE, DeVries A, Sullivan MD. Factors Associated With Chronic and Non-Chronic Opioid Initiation in Persons With Chronic Non-Cancer Pain" poster presented at the 31st Annual Scientific Meeting of the American Pain Society, May 17, 2012, Honolulu, HI
30. Patil P, Said Q, Thomas J, Wolfe J, **Martin B**. "A Descriptive Study of Opioid Use In The Management Of Diabetic Peripheral Neuropathy (DPN) In a Large Commercially Insured Population" poster presented at the ISPOR 17th Annual International Meeting in Washington, DC, June 2012, USA. Value in Health 15 (4) : A188.
31. Gokhale M, Cleves M, Foster H, James L, Hogan W, **Martin BC**. "Relationship Between Prescription Acquired Acute and Chronic Acetaminophen Use and Liver toxicity" poster presented at the ISPOR 14th Annual European Congress, November 2011, Madrid, Spain. Value in Health 14 (7):A391-A392.
32. Ali MM, **Martin BC**. "Trends In On-Label And Off-Label Prescribing Of Montelukast In A Commercially Insured Population 1998-2008" poster presented at the ISPOR 16th Annual International Meeting, May 2011 Baltimore, MD, USA. Value in Health 14(3):A15-A15



33. **Martin BC**. Casciano JP, Kwong WJ, Singer DE. Can a Model-Based Decision Support Tool Improve Anticoagulation Outcomes for Atrial Fibrillation? Results from a Large Database Cohort. Poster presented at the American Heart Association 2011 Scientific Sessions; November 13, Orlando, Florida. 2011.
34. **Li C, Martin BC**, Cummins DF, Andrews LM, Frech-Tamas F, Yadao AM. Ambulatory resource utilization and cost for gouty arthritis and gouty arthritis attacks. Poster presented at 2011 Annual Scientific Meeting of American College of Rheumatology/ Association of Rheumatology Health Professionals, Chicago, IL; November 4 -9, 2011.
35. **Martin BC**. Defining the clinical risks for bleeding in AF: Optimization of patient and treatment outcomes. Oral symposium presentation at the International Society on Thrombosis and Haemostasis. Kyoto, Japan, July 24, 2011.
36. **Li C, Martin BC**. Access to medical home and quality of care in adult diabetes patients. 8th World Congress of International Health Economics Association (iHEA), Toronto, Canada; July 10-13, 2011 (Oral presentation).
37. **Li C, Martin BC**. Disparity in access to usual source of care in adult diabetes patients. 2011 AcademyHealth Annual Research Meeting, Seattle, WA; June 12-14, 2011 (Poster presentation).
38. **Bhurke S, Martin BC**, Li C, Franks A, Bursac Z, Said Q. “The effect of interactions between clopidogrel and proton pump inhibitors on adverse cardiovascular outcomes in commercially insured patients with acute coronary syndrome” poster presented at ISPOR international meeting, Baltimore, MD, May 2011, Value in Health, 2011; 4: A34.
39. Said Q, **Martin BC**, Joish VN, Gabriel P, Kreilick C, Seal B, Williamson T, **Mathai SC**. Cost of Managing Chronic Thromboembolic Pulmonary Hypertension to Managed Care. Poster presentation at ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
40. Said Q, **Martin BC**, Joish VN, Gabriel P, Kreilick C, **Mathai SC**. Cost of Managing Pulmonary Arterial Hypertension to Managed Care. Poster presentation at the 11th Annual Health Services & Outcomes Research Conference. Texas Medical Center, Houston, TX. December 9, 2010.
41. Bodhani A, **Li C, Martin BC**. Physician and patient factors predicting the prescribing of statins in hypertension and diabetes. Value in Health, May/June 2008; 11(3): A212.
42. **Gokhale M, Martin BC**. Temporal association between prescribed opioids and the national death rate due to opioid poisoning. A podium presentation at the Southern Pharmacy Administration Conference, Memphis, June 2010.

43. Gokhale M, **Martin BC**. Trends in prescription acquired acetaminophen use and overuse in a commercially insured population: 2001-2008. A poster presentation at the Southern Pharmacy Administration Conference, Memphis, June 2010.
44. Dhamane AD, **Martin BC**, Brixner DI, Hudson TJ, Said Q. Assessment of Metabolic Monitoring of Patients Prescribed Second Generation Antipsychotics Using Electronic Medical Record Data. Accepted for poster presentation at the ISPOR 15th Annual International Meeting, Atlanta, GA, May 15-19, 2010.
45. Rascati KL, **Martin BC**, Cheng L Severity Scoring: Comparison of Methods (workshop presentation). ISPOR 2nd Latin America Conference, Rio de Janeiro, Brazil, September 9-12, 2009.
46. Pyne JM, Bodhani A, **Martin BC**. “The Cost Effectiveness of Genetic Metabolic Screening Prior to Initiating Antidepressant Therapy.” Poster Presentation, February 2009, VA HSR&D Annual Meeting, Washington, DC.
47. **Martin BC**, Cox E. “The Validity of Electronic Prescription Claims Data: A comparison of electronic prescription claims records with pharmacy provider records” presented at the ISPOR 11th Annual European Congress, November 2008 Athens, Greece. *Value in Health*. 11( 6):A564-A564.
48. Flannigan K, **Martin BC**. “A Natural Experiment To Estimate The Impact Of A Preferred Drug List Policy For Long Acting Narcotic Analgesics On Costs And Utilization” presented at the ISPOR 11th Annual European Congress, November 2008 Athens, Greece. (*Value in Health 11.6 (2008): A648-A649*)
49. **Martin BC**, Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath B. A New Measure of Adherence – the Daily Possession Ratio (DPR): Comparisons with the Medication Possession Ratio (MPR) in the presence of medication switching and therapeutic duplication. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Toronto, Canada, May 5, 2008. (*Value in Health 2008; 11(3):A124-A125*).
50. Parikh K, Li C, **Martin BC**. Factors Associated With Antihistamine Prescribing in Asthma in The United States during 2005. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Toronto, Canada, May 6, 2008. (*Value in Health 2008; 11(3):A280*).
51. Bodhani A, Li C, **Martin BC**. Physician and Patient Factors Predicting the Prescribing of Statins in Hypertension and Diabetes. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th annual meeting. Toronto, ON, Canada, May 6, 2008. (*Value in Health 2008; 11(3): A212*).
52. Pathak P, West DS, **Martin BC**, Helm M, Henderson C. An Investigation of Evidence-Based Use of Atypical Antipsychotics in Arkansas Medicaid. Poster presentation at the

International Society for Pharmacoeconomics and Outcomes Research. Toronto, Canada. May 5, 2008. (*Value in Health* 2008; 11(3): A130-A131).

53. **Conrad RC, Martin BC.** Impact of 3-tier prescription copayment on prescription discontinuation and switching behavior of military beneficiaries. Joint Services Pharmacy Seminar. (*JAPhA* 2007; 47(5): 633).
54. **Parikh K, Martin BC.** Trends in Antihistamine Prescribing for Asthma in the United States from 1993-2004. Poster Presentation at the 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management annual meeting. Quebec City, Canada, August 20, 2007.
55. **Martin BC,** Pathak P, Helm M. The Impact of a Calcium Channel Blocker Preferred Drug List on Medicaid Prescription Expenditures and Utilization. Podium Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A3).
56. **Martin BC,** Karve SJ, Helm M. Having your Cake and Eating it Too: Results from a Policy Analysis of a Proton Pump Inhibitor Preferred Drug List. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A150).
57. **Karve SJ, Martin BC.** The Predictive Validity of Different Adherence Measures using Administrative Claims Data. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A85).
58. **Bodhani A,** Karve SJ, **Martin BC.** Trends in the Off-Label Prescribing of 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors in the United States: 1998-2004. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A48).
59. **Pathak P, Martin BC.** The Trends in Prescribing of Herbal Medicines in Ambulatory Settings in the United States 1993-2004. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A25).
60. **Martin BC,** Karve S, Helm M. Costs Reductions Attained from an Evidence Based Preferred Drug List Policy on Less Sedating Antihistamines in a Medicaid Population. Poster presentation Academy of Managed Care Pharmacy Meeting, April 13, 2007. (*JMCP* 2007;13(2):175).
61. **Martin BC,** Pathak P, Helm M. Costs Reductions Attained from an Evidence Based Preferred Drug List Policy on HMG-CoA Reductase Inhibitors in a Medicaid Population. Poster presentation Academy of Managed Care Pharmacy Meeting, April 13, 2007. (*JMCP* 2007;13(2):175).

62. **Martin BC**, Hudson T, Constantine R, Wells J. Financial Evaluation of the Florida Medicaid Behavioral Pharmacy Management Program (BPMP). Poster presentation at the 2006 Medicaid Summit Conference, Park City, UT, September 28, 2006.
63. **Martin BC**, Karve S, Helm M. Costs Reductions Attained from an Evidence Based Preferred Drug List Policy on Less Sedating Antihistamines in a Medicaid Population. Poster presentation at the 2006 Medicaid Summit Conference, Park City, UT, September 28, 2006.
64. **Karve SJ, Martin BC**. Trends in Ambulatory Care Utilization for Constipation and Irritable Bowel Syndrome 1993-2003. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Philadelphia, PA, May 21, 2006. (*Value in Health 2006; 9(3):A48*).
65. **Chen H, Martin BC**. The Impact of Prescribing Off-Label Mood Stabilizers for Patients with Schizophrenia. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Philadelphia, PA, May 21, 2006. (*Value in Health 2006; 9(3):A72*).
66. **Martin BC, Barghout V**. "Compliance and Persistence of Tamoxifen and Aromatase Inhibitors in Breast Cancer Patients." 5th European Breast Cancer Conference (EBCC), 21st - 25th March 2006, Nice, France.
67. Chen H, **Martin BC**. Prevalence and Factors Associated with the Off-Label Use of Antipsychotic, Antidepressant, and Anticonvulsant Medications among Georgia Medicaid Eligibles. Poster Presentation at the International Society for Pharmacoepidemiology (ISPE) annual meeting. Nashville TN, August 22, 2005. (*Pharmacoepidemiology and Drug Safety 2005; 14(S2): S20-S21*).
68. **Sapra S, Martin BC**. Impact of Anti-Allergic Medication on Asthma Costs in a Pediatric Population. Poster presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Washington DC, May 16, 2005. (*Value in Health 2005; 8(3): 258*).
69. Cantrell RC, **Martin BC**. Development and Validation of a Claims-Based Risk Assessment Model to Predict Pharmacy Expenditures in a Commercial Population. Poster presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Washington DC, May 16, 2005. (*Value in Health 2005; 8(3): 294*).
70. **Martin BC, Barghout V**. The annual cost of constipation in the U.S. ambulatory and inpatient care settings. Poster presentation during Digestive Disease Week, McCormick Place in Chicago, Illinois, May 14-19, 2005.

71. **Martin BC, Barghout V.** National estimates of office and emergency room constipation-related visits in the United States. A Poster Presentation at the American College of Gastroenterology, Orlando, FL, October 2004.
72. **Martin BC, Barghout V.** National Estimates of Constipation Related Hospitalizations in the United States. A Poster Presentation at the American College of Gastroenterology, Orlando, FL, October 2004.
73. **Jiang J, Martin BC.** Cost-Effectiveness Analysis Comparing COX-2-specific inhibitors with conventional NSAIDs. Presented at the Southern Pharmacy Administration Conference 2004, Fort Lauderdale, FL, June 12, 2004.
74. **Martin BC,** Miller LS, Dorfman J, Kotzan JA. Advancing Risk Adjustment for Schizophrenia. Presented at the Annual International Society for Pharmacoeconomics and Outcomes Research European Conference, Barcelona, Spain. November 10, 2003.
75. **Ganguly R, Miller LS, Martin BC.** Prevalence and Trends in Antipsychotic Polypharmacy among Medicaid eligible Schizophrenia Patients in California and Georgia, 1998-2000. Presented at the 8th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington DC. May 19, 2003. (*Value in Health* 2003; 6(3): 347-8).
76. **Pannicker S, Nielsen K, Martin BC.** The Net Cost of Asthma to North Carolina (NC) Medicaid and Identification of Factors Driving Costs in an Asthmatic Population. Presented at the 8th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington DC. May 19, 2003. (*Value in Health* 2003; 6(3): 368).
77. **Ganguly R., Martin BC, Dorfman JH, Rizzo JA.** "In search of an unbiased estimate of treatment effect using observational data: A comparison of propensity scoring and heckman two stage sample selection models" A one hour workshop presented at the 8<sup>th</sup> Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington DC. May 19, 2003.
78. **Koompalum D, Martin BC.** "Factors Influencing Inappropriate Antibiotic Prescribing for Children with Acute Bronchitis in Ambulatory Care Setting" a poster presentation at the 2002 International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress, Rotterdam, Netherlands, November 4, 2002 (*Value in Health* 2002; 5(6): 574-5).
79. **Niecko T, Kotzan JA, DiPiro JT, Martin BC.** "Nonsteroidal Anti-Inflammatory Drug Exposure and the Relative Risk of Colorectal Cancer, Gastrointestinal and Renal Adverse Events" a podium presentation at the International Conference on Pharmacoepidemiology, Edinburgh, Scotland, August 21, 2002. (*Pharmacoepidemiology and Drug Safety* 2002; 11: s4).

80. Provost M, Koompalum D, Dong D, Cox C, **Martin BC**. "The initial development of the WebMedQual: a scale to assess the quality of health web sites" a poster presentation at the Drug Information 2002 Annual meeting, Chicago, IL.
81. Panicker S, Barghout VE, **Martin BC**. "The economic burden of Irritable Bowel Disease (IBS) to the North Carolina Medicaid program" a podium presentation at the Digestive Disease Weekly (DDW (2002)) Conference, San Francisco, California, May 22, 2002. (*Gastroenterology 2002;122(4):A687*).
82. Ganguly R, **Martin BC**. "Antipsychotic polypharmacy: Impact on cost and community tenure" a podium presentation at the Southern Pharmacy Administration 2002 Conference, Monroe, Louisiana, June 9, 2002.
83. Provost M, Koompalum D, Dong D, Cox C, **Martin BC**. "The initial development of the WebMedQual: a scale to assess the quality of health web sites" a poster presentation at the Southern Pharmacy Administration 2002 Conference, Monroe, Louisiana. Jun 8, 2002.
84. Panicker S, **Martin BC**. "The net cost of asthma to the North Carolina (NC) Medicaid and the impact of varying case definitions" a poster presentation at the Southern Pharmacy Administration 2002 Conference, Monroe, Louisiana, Saturday, June 8, 2002.
85. Niecko T, Kotzan JA, DiPiro JT, **Martin BC**. "Nonsteroidal Anti-Inflammatory Drug Exposure and the Relative Risk of Colorectal Cancer, Gastrointestinal and Renal Adverse Events," a poster presentation at the Biomedical and Health Sciences Institute Annual Spring Symposium 2002: Cancer Research in Georgia, Athens, GA; June 3, 2002.
86. Pannicker S, Nielsen K, **Martin BC**. "The Net Cost of Asthma to a U.S. Public Medicaid Program," a podium presentation at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting, Cannes, France, November 13, 2001. (*Value in Health 2001; 4(6): 419*).
87. Ricci JF, Silverstein MS, **Martin BC**. "Development and validation of a prospective mortality risk adjustment casemix index using administrative drug information in ambulatory Medicaid populations," a podium presentation at the American Public Health Association, 129th Annual Meeting, Atlanta, GA, October 2001.
88. Ricci JF, Kotzan JA, **Martin BC**. "Development and validation of prospective mortality risk adjustment casemix indices using administrative drug information to supplement ICD-9-CM codes in ambulatory Medicaid populations," a poster presentation at the American Public Health Association, 129th Annual Meeting, Atlanta, GA, October 2001.
89. Fagan SC, **Martin BC**, Cantrell CR, Hess DC: "Secondary Stroke Prevention Gap." a poster presentation at the First National CDC Prevention Conference on Heart Disease and Stroke , Atlanta, GA, August 22-24, 2001. (*Preventive Med 2001;33: S28*).

90. Ganguly R, Barghout V, Frech F, **Martin BC**. "The Economic Burden of Irritable Bowel Syndrome to Medicaid" a poster presented at the 2001 American College of Gastroenterology annual meeting, Las Vegas, NV, October 23, 2001.
91. Ricci JF, Fagan S, Martin BC. "Development and Independent Validation of Prospective Mortality Risk-Adjustment Models for Incident Cases of Ischemic and Hemorrhagic Stroke Based on Automated Pharmacy and Medical Claims Data" a podium presentation at the American Neurologic Association Annual Meeting, Chicago, IL, Sept 30, 2001.
92. Martin BC, Silverstein MD, Ricci JF.. "Development and Independent Validation of Prospective Mortality Risk Adjustment Models for Alzheimer's and Related Dementias Based on Automated Pharmacy and Medical Claims Data," a poster presentation at the American Neurologic Association Annual Meeting, Chicago, IL, Sept 30, 2001.
93. Ricci JF, Silverstein MS, Fagan SC, Martin BC. "Development and Validation of Prospective Cost Risk Adjustment Indices Using Administrative Medical and Drug Information for Stroke Patients in Medicaid Populations," a poster presentation at the Academy for Health Services Research and Health Policy, 2001 Annual Meeting, Atlanta, GA, June 2001.
94. Ricci JF, Silverstein MS, Kotzan JA, **Martin BC**. "Development and Validation of Prospective Cost Risk Adjustment Indices Using Administrative Medical and Drug Information for Medicaid Eligible Alzheimer's Dementia Patients," a poster presentation at the Academy for Health Services Research and Health Policy, 2001 Annual Meeting, Atlanta, GA, June 2001.
95. Ricci JF, Dorfman JH, **Martin BC**. "Development and Validation of Prospective Cost Risk Adjustment Indices Using Administrative Medical and Drug Information for Medicaid Populations," a poster presentation at the Academy for Health Services Research and Health Policy, 2001 Annual Meeting, Atlanta, GA, June 2001.
96. Ganguly R, Nerurkar J, **Martin BC**. "An assessment of the reliability and validity of the Cognitive Performance Scale (CPS) on the Medical Expenditure Panel Survey-Nursing Home Component" a poster presentation at the 2000 American Public Health Meeting, Boston, MA, November 15, 2000. (*pg 620 of the Meeting Program Announcement*).
97. Cantrell R, Young F, **Martin BC**. "Decision Analysis of Omeprazole versus Laparoscopic Nissen Fundoplication for Treating Patients with Severe Gastroesophageal Reflux Disease" a poster presented at the ISPOR Third Annual European Conference, Antwerp, Belgium, November 6, 2000. (*Value in Health. 2000; 3(5): 357*).
98. Nerurkar J, Wade WE, Martin BC. "Prophylaxis Against Deep-Vein Thrombosis and Fatal Pulmonary Embolism in Knee Arthroplasties: A Cost-Effectiveness Study" a poster presented at the ISPOR Third Annual European Conference, Antwerp, Belgium, November 5, 2000. (*Value in Health. 2000; 3(5): 313*).

99. Kotzan JA, **Martin BC**, Wade WE, Yu K. "GI Events Associate with NSAID Use in a Medicaid Population" a podium presentation at the 1999 American Association of Pharmaceutical Scientists Annual Meeting.
100. Cantrell R, Young F, **Martin BC**. Antibiotic Prescribing in Ambulatory Care Settings for Adults with Colds, Upper Respiratory Tract Infections and Bronchitis" a podium presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
101. Gedaly S, Panicker S, Menon A, **Martin BC**. "Geographic Variations in the Rates of Total Joint Arthroplasty" a podium presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
102. Ganguly R, Miller LS, **Martin BC**. "Cost-Effectiveness Analysis of Risperidone Using Work Status as an Outcome Measure" a podium presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
103. Cantrell R, Koompalum D, **Martin BC**. "Antibiotic Prescribing for Children with Colds, Upper Respiratory Tract Infections and Bronchitis in Ambulatory Care Settings" a poster presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
104. Joseph GJ, Banavali R, **Martin BC**. "Does the Lunar Cycle Affect the Need for Urgent Care? An Analysis of the 19996 NHAMCS Database" a poster presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
105. Ricci JF, Dorfman JH, **Martin BC**. "Improving upon Modeling of Cost Outcomes" a podium presentation at the 1999 Society for Medical Decision Making Annual Meeting, Reno NV, October 4, 1999.
106. Glick HA, Polsky D, Schulman KQ, **Martin BC**, Oconner CM. "An Economic Evaluation of Amlodipine for the Treatment of Nonischemic Dilated Cardiomyopathy: The Prospective Randomized Amlodipine Survival Evaluation (PRAISE)" a podium presentation to the 4<sup>th</sup> European Meeting on Calcium Antagonists, Amsterdam, October 1999.
107. Radensky PW, O'Conner CM, Unger AN, **Martin BC**. "Hospital Utilization and Cost Among Patients with Nonischemic Heart Failure in the First Prospective Randomized Amlodipine Survival Evaluation Study (PRAISE)" a podium presentation to the 1999 International Society of Pharmacoeconomics and Outcomes Research annual meeting, May 1999 (*Value in Health*. 1999;2:129).
108. **Martin BC**, Pathak DS, Kwong WJ, Batenhorst AS, Sharfman MI. "Assessment of Responsiveness of the Migraine-Specific Quality of Life Questionnaire [Version 2.0]" a poster presentation at the Sixth Annual Symposium on Quality of Life Evaluation, Drug Information Association, Hilton Head, SC, March 1999.



109. Pathak D, Martin BC, Kwong J, Batenhorst A. Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.0) using confirmatory factor analysis. (*Quality of Life Research*. 1998;7:647).
110. Battle YL, **Martin BC**, Dorfman JH, Miller LS. Seasonality and Infectious Disease in Schizophrenia: The Birth Hypothesis Revisited” a poster presentation at the 1999 International Congress on Schizophrenia Research, Santa Fe, NM, April 1999. (*Schizophrenia Research*. 1999;36:37).
111. **Martin BC**, Miller LS. “Six-Year Service Utilization and Expenditures of Medicaid Eligible Schizophrenia Patients In the State of Georgia” a poster presentation at the 1999 International Congress on Schizophrenia Research, Santa Fe, NM, April 1999. (*Schizophrenia Research*. 1999;36:346).
112. Ricci JF, Martin BC. "Development and Validation of Empirically Derived Risk-Adjustment Indexes for a Demented Population," a podium presentation at the 1998 Society for Medical Decision Making Annual Meeting, Boston, MA, October 1998. (*Medical Decision Making*. 1998;18(4):476).
113. **Martin BC**, Ricci JF, Kotzan JA, Menzin J, Lang K. “The burden of Alzheimer’s Dementia to Georgia Medicaid” a podium presentation at the 1998 Neurology Outcomes Research: Current Science and Future Direction Conference, American Neurologic Association, Montreal, Canada, October, 1998. (*Annals of Neurology* 1998;44(3):5).
114. Martin BC, Sharfman M, Pathak D, Kwong J. “Assessment of Reliability of the MSQ, the Migraine Specific Quality of Life Questionnaire [Version 2.0]” a poster presentation at the 1998 Neurology Outcomes Research: Current Science and Future Direction Conference, American Neurologic Association, Montreal, Canada, October, 1998. (*Annals of Neurology* 1998;44(3):p4).
115. **Martin BC**, Chisolm MA. Validation of an Instrument to Measure Pharmacy Students Attitudes Concerning Pharmaceutical Care” an abstract accepted for a poster presentation at the 1998 American Association of College of Pharmacy Annual meeting, Snowmass, CO, July 21, 1998.
116. Ricci JF, Martin BC. "Development and Cross-Validation of a Comorbidity Index for a Stroke population" a podium presentation at the 1998 International Society for Pharmacoeconomics and Outcomes Research annual meeting, Philadelphia, PA, May 1998. (*Value in Health*. 1998;1:33).
117. **Martin BC**, Kotzan JA, Reeves J. "The Direct Medical Cost of Osteoporotic Fractures" a poster presentation at the 1998 International Society for Pharmacoeconomics and Outcomes Research annual meeting, Philadelphia, PA, May 1998. (*Value in Health*. 1998;1:65).
118. Kotzan JA, Martin BC, Reeves J. "Fracture Incidence in a Post Menopausal Female Medicaid Population" a podium presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.

119. Ricci JF, **Martin BC** "Resource Utilization of Ischemic Stroke Patients: A Population Based Study of Georgia Medicaid Recipients" a podium presentation at the 1997 American Association of Pharmaceutical Scientist, Boston MA, November 1997.
120. Kotzan JA, **Martin BC**, Reeves J, Nichols G. "Hormone Therapy Compliance for Post Menopausal Medicaid Patients" a podium presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.
121. Oh S, Ricci JF, Gedaly S, Cook C, Chaffee A, Misra S, Arocho R, McMillan CA, **Martin BC** "Preliminary Results from a Multi-Regional Survey of Women Pharmacists: Baseline estimates of Risk Factors and Disease Events" a poster presentation at the 1997 American Association of Pharmaceutical Scientist, Boston , MA, November 1997.
122. Burgess SM, Chaffee AD, **Martin BC** "Variations in Immunization Rates for Children" a poster presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, IN, November 1997.
123. Gedaly S, Oh S, Ricci JF, Cook C, Chaffee AD, Burgess S, Arocho R, McMillan CA, **Martin BC** "Results for a Multi-Regional Survey of Women Pharmacists. Focus on Spontaneous Abortion" a poster presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.
124. Chaffee AD, Ricci JF, Gedaly S, Oh S, Cook C, Burgess S, Arocho R, McMillan CA, **Martin BC** "Prevalence and Risk Factors Associated with Migraine Headaches in Women Pharmacists: An Exploratory Analysis for a Multi-Regional Survey" an abstract printed in the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.
125. Reeves JH, Kotzan JA, **Martin BC**, "The Impact of Fractures and Race On Mortality: A Retrospective Survival Analysis of Post-Menopausal Female Medicaid Recipients," an abstract accepted for a podium presentation at the 1997 American Public Health Meeting, Indianapolis, IN, November 9-13, 1997.
126. Boudinot SG, **Martin BC**, "Factors Influencing Pharmaceutical Calculations Grades: Is more study time better?" a poster presentation at the 1997 American Association of College of Pharmacy Annual meeting, Indianapolis, IN, July 15, 1997.
127. Ricci JF, Oh S, **Martin BC**, "Meta-Analysis, Markov Decision Tree, and Cost-Effectiveness Analysis on the Treatment of Essential Hypertension in the Elderly," and abstract accepted for a contributed podium presentation in the section entitled "Hypertension: Identification of Patients and Costs" of the Association for Pharmacoeconomics and Outcomes Research Annual Meeting, Philadelphia, PA, April 25, 1997.
128. Martin BC, Dorfman JH. "Bootstrapping Confidence Intervals and Mean Variances" a podium presentation at the 1996 Southeastern SAS users group, Atlanta, GA, October 14, 1996.

129. Ricci JF, **Martin BC**. "Institutionalized Resource Utilization of Ischemic Stroke Patients: A Population Study of Georgia Medicaid Recipients" a podium presentation at the 1996 Southern Pharmacy Administration Conference, Oxford, MS, May 31, 1996.
130. Misra S, Horvath B, Chaffee AD, **Martin BC**. "Variations in Immunization Rates for Children." a podium presentation at the 1996 Southern Pharmacy Administration Conference, Oxford, MS, May 31, 1996.
131. **Martin BC**. "Predicting Success in a Pharmacy Finance Course: Where Did you do your Pre-Pharmacy Curriculum?" a poster presentation at the 1996 American Association of College of Pharmacy Annual meeting, Reno, NV, July 17, 1996.
132. **Martin BC**. "Assessing Student Perceptions of Courses Offered by Pharmacy Care Administration" a poster presentation at the 1996 American Association of College of Pharmacy Annual meeting, Reno NV, July 17, 1996.
133. Misra S, Ricci JF, **Martin BC**, Gedaly S, Clark G, Kamath A, Horvath B. "An Appraisal of Generic Quality of Life Scales in Three Disease Management Areas: Hypertension, Diabetes, and Asthma," a poster presentation at the 1995 Academy of Managed Care Pharmacy, Washington, DC, November 1995.
134. Kotzan JA, **Martin BC**, Perri M. "A Market Share Analysis for Prior Authorized Medicaid Prescriptions," a podium presentation at the 1995 Annual American Association of Pharmaceutical Scientist.
135. **Martin BC**, Nadipelli V. "The Direct Medical Costs of Schizophrenia: A Population-Based Study of Georgia Medicaid Recipients," a poster presentation at the 1995 Association for Health Services Research Annual Meeting, Chicago, IL, June 1995.
136. Kotzan JA, Perri M, **Martin BC**. "Prescription Utilization for Medicaid Patients," a podium presentation at the 1995 American Pharmacy Association Annual Meeting, Orlando, FL, March 18, 1995.
137. **Martin BC**, Perri M, and Kotzan JA. "Care Seeking Behavior and the Role of the Pharmacist," a podium presentation at the 1995 American Pharmacy Association Annual Meeting, Orlando, FL, March 19, 1995.
138. Kamath AR, **Martin BC**, and Kotzan JA. "Documenting Pharmacist Interventions - A Telephonic Approach," a poster presentation at the 1994 Southern Pharmacy Administration Conference, Gainesville FL, June 4, 1994.
139. **Martin BC** and McMillan JA. "The Impact of A Finite Prescription Limit on Medicaid Recipients: Effects on Cost, Therapy, and Out-of-Pocket Expenditures," a poster presented at the 11th Annual Meeting of the Association for Health Services Research, San Diego, CA, June 13, 1994.

140. **Martin BC** and McMillan JA. "Bias Associated with Incomplete Data for Medicaid Recipients: The Whole Truth," poster presented at the 11th Annual Meeting of the Association for Health Services Research, San Diego, CA, June 13, 1994.
141. **Martin BC** and McMillan JA. "Revealed Preferences of Prescriptive Medicines," a poster presented at the 11th Annual Meeting of the Association for Health Services Research, San Diego, CA, June 13, 1994.
142. **Perri M**, and **Martin BC** "An Exploratory Study of a Practical Intervention for Improving Medication Compliance," Presented at the National Conference on Prescription Medicine Information and Education, Washington D.C., May 6, 1993.
143. **Martin BC**, McMillan JA, Dorfman JH, and Jankel CA "Prevalence of Migraine Headache in the Georgia Medicaid Population," A poster presentation at the American Public Health Association Annual Meeting, Washington, D.C., November 10, 1992.
144. **McMillan JA**, **Martin BC**, and Jankel CA, "Migraine-Related Utilization and Costs in A Medicaid Population," a poster presented at the Ninth Annual Meeting of the Association for Health Services Research, Chicago, Illinois, June 11, 1992.
145. **Jankel CA**, **McMillan JA**, and **Martin BC**, "The Cost of A Drug Interaction in Two Maryland Hospitals," a poster presented at the Ninth Annual Meeting of the Association for Health Services Research, Chicago, Illinois, June 11, 1992.
146. **Martin BC**, Jankel CA, and McMillan JA, "Selecting Ordinary Least Squares Estimators: A Case Examination of Collinear Control Variables," a podium presentation at the Southern Pharmacy Administration Conference, Auburn, Alabama, May, 1991.
147. **Martin BC** and Jankel CA, "Computer Drug Interaction Screening: An Evaluation of Current Software and Steps for Evaluating Software by Practitioners," a podium presentation at the 25<sup>th</sup> annual American Society of Hospital Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 4, 1990.
148. **Ortmeier BG**, **Martin BC**, and Wolfgang AP, "Stress Perception and Career Commitment: A Survey of Pharmacy Students," a poster presented at the 91st Annual Meeting of the American Association of Colleges of Pharmacy, Salt Lake City, Utah, July 10, 1990.

## INVITED PRESENTATIONS AT INTERNATIONAL, NATIONAL, AND REGIONAL PRESENTATIONS

149. Opioid use trajectories: An analysis of over 1 million non-cancer patients initiating opioids. Plenary Speaker. National Alliance of Medicare Set-Aside Professionals. MSP Policy Palooza, Baltimore, MD, September 27, 2017
150. The Opioid Epidemic. Plenary Speaker. Louisiana Department of Insurance Annual Health Care Conference. Baton Rouge, LA, September 7, 2017
151. Making Medical Decisions In An Irrational World. Plenary Address. 2016. International Society for Pharmacoeconomics and Outcomes Research International Conference, Washington, DC, May 24, 2016.
152. Opioids, A Friend for Life? Roundtable presented at the Southern Pharmacy Administration Conference. June 26, 2016.
153. Assessing the Evidence for the Health Care Decision Maker. Plenary Address. 2013 International Society for Pharmacoeconomics and Outcomes Research Conference, New Orleans, LA, May 20, 2013.
154. Assessing the Evidence Toolkit: Increasing the Reliability and Consistency of Evidence Evaluation. Webinar for Academy of Managed Care Pharmacy. October 30, 2013 & November 13, 2013.
155. Health evidence for decision making: assessment tool for prospective and retrospective observational studies. 2012 European ISPOR Conference, Berlin, Germany, November 5, 2012.
156. A proposed "measurement tool" for assessing retrospective observational studies for health care decision makers, Presented Moderator & Speaker: Bradley Martin, PhD, RPh, PharmD, Chair will be presented as one of the work products developed by Part 1 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative, June 5, 2012, ISPOR International Conference, Washington DC
157. Eldessouki R, Berger M, Jansen J, Eddy D, Martin BC, Comparative Effectiveness Research Collaborative Initiative (CER-CI), Part 1- Interpreting Outcomes Research Studies for Health Care Decision Makers, Academy of Managed Care Pharmacy, April 20, 2012, San Francisco, CA
158. Michael Johnson Marc Berger, Muhammad Mamdani, Colin Dormuth, William Crown, PhD, Bradley Martin PhD, Emily Cox. Design and Analysis of Non-Randomized Studies of Treatment Effects using Secondary Databases. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Forum, Orlando, May 2009.

159. Direct Medical Costs of Constipation in the United States. GI Journal Club - National Internet CME presentation. March 5, 2007.
160. Martin BC, Barghout V. "Compliance and Persistence of Tamoxifen and Aromatase Inhibitors in Breast Cancer Patients." 2007 Presidents Day Weekend Breast Cancer Challenge. Branson, MO. February 19, 2007.
161. Martin BC. "Prescription Drug Event Data for Medicare Beneficiaries: A Glimpse of What the Part-D Research Data May Look Like" and invited podium presentation to the Student Forum of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 21, 2006.
162. Martin BC. "The Direct Costs of IBS and Constipation" Presented to the Novartis Health Outcomes Group, Newark, NJ, November 12, 2004.
163. Martin BC, Ganguly R, Dorfman J, Rizzo J. "In Search of an Unbiased Estimate of Treatment Effect Using Observational Data: A Comparison of Propensity Scoring and Heckman Two-Stage Sample Selection Models" an invited seminar presented to the Emory Cardiology Outcomes Group, Emory University, Atlanta GA, June 27, 2003.
164. Miller LS, Martin BC, Kotzan JA, Kennedy K, Ganguly R, Dorfman J. "Schizophrenia Treatment Patterns: Uses and limitations of Epidemiological Data sets," Invitational Address to the Psychology Department, University of South Alabama. April 11, 2003.
165. Martin BC. "The report of the ISPOR Retrospective Database Task Force" International Society for Pharmacoeconomics and Outcomes Research, Crystal City, VA, May 21, 2002.
166. Martin BC. "Economic and Clinical Management of H. Pylori Induced Peptic Ulcer Disease," Athens Area Health Plan Select HMO Physician Group, Athens, GA, November 11, 1998.
167. Martin BC. "How Much Does an Illness Cost? The Case of Osteoporosis and Alzheimer's Disease," an invited seminar presentation, Department of Clinical and Administrative, College of Pharmacy, Athens, GA, December 1998.
168. Martin BC. "Caveats with Administrative Data: Lessons learned from policy analyses and a study of schizophrenia" and invited seminar presentation, College of Pharmacy, The Ohio State University, February 23, 1998.
169. Kotzan JA, Martin BC, Reeves J, "Issues Relating to Osteoporosis in Post Menopausal Georgia Medicaid Patients" Georgia Department of Medical Assistance, July 23, 1997.
170. Martin BC, Radensky P, "Hospital Resource Utilization within a Clinical Trail for Congestive Heart Failure Patients" Outcomes Research Group, Pfizer Inc., New York NY, November 11, 1996.

171. Perri M, Martin BC, "Improving Medication Compliance: A Practical Intervention," Sterling Rice Consultants, Boulder CO, February 7, 1994.
172. Martin BC, "Pharmacokinetic Principles and Therapeutic Drug Monitoring," presented to Pharmacy Staff at Saint Anthony's Hospital, Rockford, Illinois, April, 1989.
173. Martin BC, "Treating Refractory Depression," presented to Psychiatric Medical, Pharmacy, and Nursing staff at the University of Illinois Hospital, Chicago, Illinois, December, 1988.

#### **WEBINARS AND OTHER ONLINE PRESENTATIONS**

174. Martin BC, Berger M. ISPOR Educational Webinar: A Tool for Assessing Evidence for Health Care Decisions I: Assessing Prospective and Retrospective Observational Studies, October 23, 2014
175. Martin BC. Assessing the Evidence Toolkit: Increasing the Reliability and Consistency of Evidence Evaluation. Webinar for Academy of Managed Care Pharmacy. October 30, 2013 and November 13, 2013.
176. Martin BC. Berger M. A Tool for Assessing Evidence for Health Care Decisions. Webinar for the International Society for Pharmacoeconomics and Outcomes Research . October 23, 2014.





developing models of primary care providers' and pharmacists' prescribing and dispensing behaviors and to develop specific recommendations for policy and interventions that our group and others can test in future studies to improve opioid-prescribing practice patterns, improve pain management, and decrease risk of opioid use disorders.

Direct cost first year: \$392,286, Total cost first year: \$455,397

Role: **Co-Investigator**

5. CMS-AR Medicaid Thompson (PI) 10/01/14 – 7/30/18  
Arkansas Health Care Independence Program (“Private Option”) Evaluation for Section 1115 Demonstration Waiver

The State of Arkansas implemented a novel approach to expand coverage for individuals newly eligible for Medicaid under the Patient Protection and Affordable Care Act (PPACA). Through a Section 1115 demonstration waiver, the State utilized premium assistance to secure private health coverage offered on the newly formed individual health insurance marketplace to those non-elderly adults who have incomes at or below 138 percent of the federal poverty level. This approach is commonly referred to as the “Private Option.” The objective of this evaluation will determine if the HCIP waiver improved access, improved care and outcomes, reduced churn, and was cost effective compared to traditional Medicaid expansion. Total Cost: \$4,684,343

Role: **Director of Quality and Utilization Evaluation**

6. 1 UL1RR029884 James/Beck (PI) 07/1/2009 – 03/31/2015  
Arkansas Center for Clinical and Translational Research Institute  
University of Arkansas for Medical Sciences

Provides infrastructure support to enhance translational research including the conduct comparative effectiveness studies.

Direct costs first year: \$2,659,252, Total Costs first year: \$3,804,051

Role: **Director of Health Data Unit**

7. ACHI Martin (PI) 08/1/2014 – 7/31/2016  
ACHI-UAMS Graduate Research Health Policy Analysis Fellowship, Arkansas Center for Healthcare Improvement

The University of Arkansas for Medical Sciences College of Pharmacy, in collaboration with the Arkansas Center for Health Improvement seeks to establish the ACHI-UAMS Graduate Research Health Policy Analysis Fellowship. These two entities will be working collaboratively to support a post-graduate fellow to conduct and support health policy research in the state of Arkansas and nationally. The fellowship is renewable.

Direct Cost first year: \$37,500, Total Costs first year: \$37,500

Role: **Fellowship director**

8. 1 R01 DA030300-01 Edlund/Hudson (Dual PIs) 07/01/2010 to 06/30/2014  
Use and Abuse of Prescription Opioids Among OEF/OIF Veterans

This project will utilize secondary data analysis of six years of VA administrative data (FY08-FY13), with separate analyses for OEF/OIF veterans and all veterans, to understand whether and how veteran-specific issues and system and provider factors affect likelihood of developing opioid use disorders (OUDs); and rigorously evaluate trends in chronic opioid use, misuse, and OUDs.

Direct costs first year: \$202,862, Total Costs first year: \$288,714, Total Costs 4 years: \$1,192,132

Role: **Co-Investigator**

9. Li C (PI), Martin BC (Co-I), Cummins D (Co-I) Ambulatory Resource Utilization for Gout and Gouty Arthritis Flares Protocol #: 131849, Novartis AG, 2/1/11 – 6/30/12, Total Cost: \$44,493, Role: **Co-Investigator**
10. Genetic Testing Decision Analysis Model for Antidepressant Treatment”. VA HSR&D Short-Term Project. Jeff Pyne, MD, PI. Brad Martin, PharmD, PhD, Co-I. Direct costs: \$29,084. April – September, 2008. Role: **Co-Investigator**
11. Helm M (PI), West DS (Co-I), Martin B (Co-I), Vanderbush R (Co-I). “Title: Improving Medication Prescribing for Arkansas Children through Off-label Education Start Date: May 1, 2007 through April 30, 2009. General Consumer and Prescriber Education Grant Program, Center for Evidence-based Policy, Oregon Health Sciences University, \$373,362, **Co-Investigator**.
12. Martin BC (Co-PI), Mays G (Co-PI), Hudson T (Co-I), Booth B (Co-I), Golden W (Co-I), Thompson J (Co-I), Steffick D (Co-I), Owen R (Co-I). UAMS Consortium for Health Service Research. Agency for Health Care Research and Quality. 5P20HS015878-02 Awarded June 1, 2006. First year funding \$249,423, total funding requested over 2 years. \$495,658. **Principal Investigator**.
13. Sullivan M (PI), Edlund M (Co-I), Martin BC (Co-I), DeVries A (Co-I), Fan MY (Co-I). Risks for Opioid Use and Abuse in Contrasting Chronic Pain Populations. National Institute on Drug Abuse. 09-30-06 to 09-30-10. 1 R01 DA022560-01. First year funding: \$295,272, **Co-Investigator**. \$1,023,373.
14. Domino M (PI), Carey T, Sleath B, Martin BC. Duration of Prescribed Medication and Adherence to Medications for Chronic Diseases, 2 year research grant. Submitted to the Robert Wood Johnson Changes in Healthcare Financing and Organization Initiative. \$174,527, UAMS Subcontract to University of North Carolina, **Co-Investigator**. \$40,891.
15. Hong SH (PI) Franks AM, (Co-I) Martin BC (Co-I). An Examination of Guideline Concordant and Discordant Calcium Channel Blocker Prescribing among Hypertensive Patients with High Risk Conditions. Novartis Pharmaceuticals Corporation. July 2005 – June 2006. **Co-Investigator** \$78,136.
16. Martin BC (PI). Utilization Patterns and Persistence of Antihormonal Therapies for Breast Cancer. Submitted to Novartis Pharmaceuticals Corporation, Awarded November 2005. 2005. **Principal Investigator**. \$24,492.

17. Hong SH (PI), Martin BC. Time and Healthcare Costs Needed to Reach Blood Pressure Control. Holston Medical Group. 2005. Awarded June 2005. **Co-Investigator**. \$40,303
18. Hudson T (PI), Martin BC (Co-PI), Owen R (Co-I), Steffick D (Co-I), Phillips M (Co-I). Evaluation of the Florida Medicaid Behavioral Pharmacy Management Program. Submitted to University of South Florida, Florida Mental Health Institute (FMHI). Notification of award March 8, 2005 – Research to Initiate November 2005. **Co-Principal Investigator** \$272,177.
19. Martin BC (PI). An Evaluation of the Effect of a Prior Authorization Requirement for Atypical Antipsychotic Medications in the Georgia Medicaid Program. Boston Health Economics. 2004-2005. Awarded November 2004. **Principal Investigator** \$18,260.
20. Martin BC (PI). An Evaluation of the Effect of a Prior Authorization Requirement for Atypical Antipsychotic Medications in the Georgia Medicaid Program. Boston Health Economics. 2003-2004. Awarded January 2004. **Principal Investigator** \$55,239.
21. Ganguly R and Martin BC. Antipsychotic polypharmacy: Impact on cost and community tenure; 2003; (**Major Professor and Faculty Supervisor**) Agency for Health Care Research and Quality - Dissertation Grant, Submitted August 15, 2002; Project was approved and funded but could not be accepted since R Ganguly graduated at the time of the award notification, May 2003.
22. Kotzan JA, Fick D, Martin BC, Franic D, Wade W, “Pharmaceutical Outcomes Research Program”, University of Georgia, Medical College of Georgia Joint Intramural Grants Program, **Co-Investigator**, \$16,416
23. Martin BC, Miller LS, Kotzan JA, Dorfman JH. Advancing Risk Adjustment for Schizophrenia; Agency for Healthcare Research and Quality, RO3 HS10815-01, 07/00 - 01/02, **Principal Investigator**, \$72,400.
24. Kotzan JA, Franic D, Martin BC, Wade WE. Prevalence of Cancer within the Georgia Medicaid Population; AstraZeneca, **Co-Investigator**, \$30,000.
25. Kotzan JA, Maclean JR, Martin BC, Wade WE. Pharmaceutical Outcomes Research Program; Joint Intramural Grants Program, University of Georgia Research Foundation and the Medical College of Georgia, 10/01-6/03, **Co-Investigator**, \$73,144.
26. Martin BC and Kotzan JA. Cost of Asthma and Comparative Outcomes in the Georgia Medicaid Population, Unrestricted Educational Grant; Glaxo Wellcome, 09/00 - 06/01, **Principal Investigator**, \$5,000.
27. Kotzan JA, Maclean R, Wade W, Martin BC, Imai H, Tadlock G. Drug Utilization: A review of patterns of prescribed medication among highest prescription users; 1999-2000 (funded 11/99), **Co-Investigator**, \$19,865.

28. Martin BC and Kotzan JA. The Managed Care Pharmacy Fellowship: Sponsored by Athens Area Health Plan Select; 1999-2002, Athens Area Health Plan Select; (funded 10/99), **Primary Fellow Supervisor (PI)**, \$18,000/year: total funding 72,000.
29. Kotzan JA, Wade W, Martin BC. "Determination of Gastrointestinal Bleeding Associate with Chronic Use of Nonsteroidal Anti-Inflammatory Agents in the Georgia Medicaid Population" Merck and Company; 1998-99, **Co-Investigator** (funded 11/98), \$14,044.
30. Martin BC and Kotzan JA. The Managed Care Pharmacy Fellowship: Sponsored by Athens Area Health Plan Select; 1998-99, Athens Area Health Plan Select; (funded 10/98), **Primary Fellow Supervisor (PI)**, \$18,000.
31. Martin BC, Kotzan JA, Ricci JF. Alzheimers Dementia: A Cost of Illness Study; 1997-98; **Principal Investigator (PI)**, Boston Health Economics; (funded 6/97), \$32,500.
32. Chisholm MA, Dipiro JT, May R, Martin BC, Optimizing Renal Transplant Medication Outcomes and Compliance Through Pharmacists Intervention, 1997-1999, **Co-Investigator**. The Mason Trust, (funded 12/96), \$331,853.
33. Martin BC and Miller LS. Schizophrenia in the Medicaid Population: A Cost of Illness Study, 1996-1998, **Principal Investigator**, American Association of Colleges of Pharmacy New Investigator Awards, (funded 8/96), \$9,964.
34. Martin BC, Chisolm M, Wade W. A Pharmacists Mediated Peptic Ulcer Disease (PUD) Management Program Within a Corporate Patient Population: An Integrated Approach, 1996-1999, **Principal Investigator**, Wal-Mart, \$35,615.
35. Kotzan JA and Martin BC. The Economic Burden of Osteoporosis and Pharmacoeconomic Impact of Alendronate: A Population Based Study of Georgia Medicaid Recipients, 1996-1997, **Co-Principal Investigator**, Merck and Co., \$19,857.
36. Kotzan JA and Martin BC. Medicaid Database - Analysis for Depression; 1996, **Co-Principal Investigator**, The Medstat Group, \$25,393.
37. Martin BC. A Market Share Analysis of Pharmaceutical Use for Georgia Medicaid Patients Suffering from Dementia; 1995-1996, **Principal Investigator**, Janssen Pharmaceutical Research Foundation, \$8,100.
38. Kotzan JA, Perri M, Martin BC, Poirier S, Pritchard FL. Attitudes and Current Pharmaceutical Care Practices of Community Pharmacists; 1995, **Co-Investigator**, University of Georgia College of Pharmacy, \$7,500.
39. Martin BC. The Economic Burden of Schizophrenia: A Population Based Study of Georgia Medicaid Recipients; 1994-95, **Principal Investigator**, Janssen Pharmaceutical Research Foundation, \$10,714.

40. Martin BC and Kotzan JA. A State-Wide Network for Recording Pharmacist Interventions; 1993-94, **Co-Principal Investigator**, The Georgia Pharmacy Foundation, \$5,181.
41. Perri M, Martin BC, Pritchard FL. Improvements in Medication Compliance: A Practical Intervention; 1993-94, **Co-Investigator**, The West Company, \$26,600.
42. Martin BC under the supervision of McMillan JA. The Impact of a Finite Prescription Limit on Georgia Medicaid Recipients: An Economic Analysis; 1992-93 **Principal Investigator**, Glaxo, Inc. \$1,635.
43. Martin BC under the supervision of McMillan JA. The Impact of a Finite Prescription Limit on Georgia Medicaid Recipients: An Economic Analysis; 1992-93 **Principal Investigator**, The UpJohn Co. \$1,135.
44. McMillan JA and Jankel CA. Burden of Migraine on the Georgia Medicaid Population; 1991-92; (**Research Associate**) Glaxo, Inc. \$21,332.
45. Jankel CA and McMillan JA. Cost of Drug Interactions in Two Maryland Hospitals; 1990-91; (**Research Associate**) Glaxo, Inc. \$14,341.
46. Jankel CA. An Evaluation of Drug Interaction Screening (CDIS) Programs; 1990-91; (**Research Associate**) University of Georgia Faculty Research Grant; \$6,000.

## **RECOGNITIONS, OUTSTANDING ACHIEVEMENTS, and LICENSURES**

1st place poster presented at PMRG (Pharmaceutical Marketing Research Group), 2017 Institute conference, October 2-4, 2017: Shah A, Shewale A, Hayes CJ, Martin BC “Cost Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis among Nonvalvular Atrial Fibrillation Patients”

Investigator Award, Substantial Contributions to the Literature of Clinical Pharmacy. Arkansas College of Clinical Pharmacy, 2016.

ISPOR Distinguished Service Award: Program Committee Co-Chair, 2016

Best Poster Presentation: Hammond D, Kathe N, Shah A, Martin BC. Cost Effectiveness of H2RAs versus PPIs for Stress Ulcer Prophylaxis in Critically Ill Patients. Southern Pharmacy Administration Conference, Oxford MS, June 26, 2016.

Best Student Poster Presentation Award: Shewale AR, Martin BC. Comparative effectiveness of rivaroxaban and standard anticoagulant therapies for prevention of primary venous thromboembolism in patients with major orthopedic surgery. A Poster Presentation at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Philadelphia, PA, USA. May 16-20, 2015.

Finalist for Society of Medical Decision Making Lusted Student Award: Shah AB, Shewale AR, Hayes C, Martin BC. Cost effectiveness of dabigatran, apixaban, rivaroxaban, edoxaban and warfarin for ischemic stroke prophylaxis among patients with atrial fibrillation: us private payer's perspective (Poster PS2-7). Society of Medical Decision Making, St. Louis, MO, USA, Oct 18-21, 2015.

ISPOR Distinguished Service Award: Task Force Chair Assessing Retrospective Studies for Health Care Decision Makers 2014

ISPOR Distinguished Service Award: Short Course Development and Quality Assurance Committee Chair (2012-2014)

Exceptional Reviewer: JMCP – 2013, 2017

Exceptional Reviewer: J Pharmacoepi and Drug Safety - 2012

Best Student Poster Award: A Natural Experiment to Estimate the Impact of a Preferred Drug List Policy for Long Acting Narcotic Analgesics on Costs and Utilization. Flannagin KR, Martin BC. 2008 International Society for Pharmacoeconomics and Outcomes Research European Conference, Athens, Greece.

AACP-AFPE Pharmacy Faculty New Investigator, 2004

American Society of Health System Pharmacy Foundation 2003 Pharmacy Practice Research Award for the research manuscript: Nerurkar J, Wade WE, **Martin BC.** (2002) "Costs Per Death Averted with Venous Thromboembolism Prophylaxis in Patients Undergoing Knee Arthroplasty or Replacement." Pharmacotherapy. 22(8): 990-1000.

AFPE Fellow: Awarded by the American Foundation for Pharmaceutical Education in 2004. Recognized as one of the Top 5% Reviewers for Journal of Managed Care Pharmacy, 2003.

Faculty Advisor for the UGA AMCP student chapter P&T competition team of Hua Chen, Jorie Cristy, Patrick Ellis, Taylor Rice who took First place at the National AMCP Competition held in Minneapolis MN on April 11, 2003.

Nominated for Best Poster Presentation at the 2003 International Society for Pharmacoeconomics and Outcomes Research Conference for the following presentation: Pannicker S, Nielsen K, **Martin BC.** "The Net Cost Of Asthma To North Carolina (NC) Medicaid And Identification Of Factors Driving Costs in An Asthmatic Population." Washington DC. May 19, 2003.

Career Development Certificate of Recognition for greatly contributing to the career development of UGA students, September 1, 2003.

Nominated for Best Poster Presentation at the at the 2002 International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress for the following presentation: Koompalum D, Martin BC. "Factors Influencing Inappropriate

Antibiotic Prescribing for Children with Acute Bronchitis in Ambulatory Care Setting”  
Rotterdam, Netherlands, November 4, 2002 (*Value in Health* 2002; 5: 574-5)

Career Development Certificate of Recognition for greatly contributing to the career development of UGA students, September 1, 2002.

Named Chair of the International Society for Pharmacoeconomics and Outcomes Research Task Force on Retrospective Data Base Studies. 2002

Selected as Gold Review Panel for the Journal of Managed Care Pharmacy 2002-03

Named in Who’s Who in Medicine and Healthcare, 4<sup>th</sup> Edition.

Named in Who’s Who Executive and Professional Registry, 2003

Recipient of the 1996 American Association of Colleges of Pharmacy New Investigator Awards, \$9,964 for the research proposal entitled "Schizophrenia in the Medicaid Population: A Cost of Illness Study"

Finalist for the (1996) Third Annual National Institutes for Health Care Management Research Award. The paper entitled "The Impact of a Prescription Limit on Medicaid Recipients: Effects on Cost, Therapy, and Out-of-Pocket Expenditures" was one of five finalist selections from the United States among refereed publications in the areas of health policy.

Rho Chi Honor Society (member)

Licensure: Georgia Registered Pharmacist #016337

NIH era Commons ID: BMARTINATUAMS

## **EDITORSHIP OR EDITORIAL BOARD MEMBER OF JOURNALS**

### **EDITORIAL BOARD MEMBER**

**Current Research and Medical Opinion**

**Journal of Managed Care Pharmacy**

**Innovations in Pharmacy (Science Editorial Team Member)**

### **JOURNAL REFEREE**

**JAMA**

**Pharmacoepidemiology and Drug Safety**  
(Rated as Among the best of all Reviewers)

**Medical Care**

**Value in Health**

**Journal of Managed Care Pharmacy**  
(Selected as Gold Review Panel)

**Schizophrenia Bulletin**

**American Journal of Hospital Pharmacy**

**The Annals of Pharmacotherapy**

**Journal of Geriatric Drug Therapy**

**Clinical Therapeutics**

**Journal of Pharmaceutical Marketing and Management**

**Clinical Gastroenterology and Hepatology**

### **GRANT REVIEW PANELS**

2015 NIH Director's Early independence Award (DP5) Special Emphasis  
Panel/Scientific Review Group 2015 / 08 ZRG1 RPHB-W (53) R



2014 – 2015 TRI Pilot Study Section

2012 CDC - U01 Research to Prevent Prescription Drug Overdoses

2008-2012 Children’s University Medical Group Grant (CUMG) Intramural Program

2011 American Association of Colleges of Pharmacy New Investigator Programs for Pharmacy Faculty, Social and Administrative Sciences Review Panel, Member

2008 Agency for Health Care Research and Quality (AHRQ): Special Emphasis panel, National Research Service Award Institutional Research Training Grant (T32), January 31 – February 1, 2008.

1997 - 1998 American Association of Colleges of Pharmacy New Investigator Programs for Pharmacy Faculty, Social and Administrative Sciences Review Panel, Member

1998 - 1999 American Association of Colleges of Pharmacy New Investigator Programs for Pharmacy Faculty, Social and Administrative Sciences Review Panel, Member

## **PUBLIC AND UNIVERSITY SERVICE**

### **PUBLIC SERVICE**

2016	<b>Baptist Medical Mission International, Pharmacist Volunteer on Peru Medical Mission.</b>
2011 – Present	<b>Arkansas Canoe Club Rescue Volunteer</b>
2008	<b>Red Cross Volunteer, Clinton Arkansas Tornado Disaster Relief</b>
2007 – 2013	<b>Arkansas Canoe Club Highway 65 Clean Up Crew</b>
2006	<b>Blankenship Conway Thanksgiving Dinner Delivery</b>
2005	<b>Faulkner County Rec. Department Assistant Soccer Coach</b>
2005	<b>Saint Josephs Hurricane Relief Supply Center, Volunteer</b>

2004-present	<b>International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Retrospective Database Development Task Force, Co-Chair</b>
2004-present	<b>International Society for Pharmacoeconomics and Outcomes Research (ISPOR), ISPOR Short Course Task Force, member</b>
2003	<b>Journal of Manage Care Pharmacy (JMCP) Award for Excellence for 2002, Judge</b>
2002-2004	<b>Mercy Clinic, Athens, GA</b> Volunteer Pharmacist
2000-2003	<b>International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Task force on Developing Guidelines for Retrospective Studies,</b> Chair 2002
2001	<b>Georgia State Science Fair, Judge</b>
2001-present	<b>University of Georgia Catholic Center,</b> Special Projects Coordinator
2000-2004	<b>Academy of Managed Care Pharmacy</b> Faculty advisor for UGA student chapter
1992 - 2004	<b>R.C. Wilson Pharmaceutical Association</b> served as treasurer 1995-1997
1994 - present	<b>Knights of Columbus (member)</b>
1998	<b>Oconee River Rendezvous Participant</b>
1994 - 1996	<b>Saint Joseph's School - (Science Fair Judge)</b>
1989-1990	<b>Athens Tutorial Center (Tutor)</b>
1993 - present	<b>Association for Health Services Research (member)</b>
1992 - 1994	<b>American Public Health Association (member)</b>
1990 - present	<b>American Association of Colleges of Pharmacy (member,</b> alternate College or Pharmacy delegate 1993, 1995, 1997)

**ADMINISTRATIVE SERVICES TO THE UNIVERSITY**

2016	COP Pharmacy Practice Seminar Committee
2016	UAMS Clinical Research Committee
2012-2016	Pharmaceutical Sciences Graduate Program Committee
2015-2016 2012-2013	Pharmaceutical Evaluation and Policy Graduate Admissions Committee
2010	ACPE Self Study Section Chair
2006-2009	Curriculum Committee, Graduate School
2008-2009	Promotion and Tenure Committee, College of Pharmacy
2005-2007	UAMS House of Delegates, member
2005-2007	UAMS Graduate Student Funding Committee, member
2002-2004	Committee for Graduate Faculty Review, member
2002-2004	College of Pharmacy Faculty Council, College wide representative
1999-2001	University Council, Executive Committee, member
1999-2001	University Council, Strategic Planning Committee, member
1998-2004	Department of Clinical and Administrative Sciences Graduate Education Committee, member
2002-2003 1998-2000	Parliamentarian, College of Pharmacy
1998-2000	College of Pharmacy Task Force on Strategic Planning, member
1997-1998	Faculty Affairs Committee of the University Council, CHAIR
1997-1998t	ACPE Self-Study Sub-Committee on Mission, Member
1999-2002 1995-1998	University Council, University of Georgia, member
1996- 1998	Faculty Affairs Committee of the University of Council, member

- 1996-2004 Computer Resources Committee, College of Pharmacy, member,  
Chair 1998-1999
- 1995 Annual Faculty Symposium sponsored by the Office of Vice President  
for Academic Affairs: Peer Review: The Scholarship of Teaching
- 1999-2002 Admissions Committee, College of Pharmacy,  
1993-1995 CHAIR 1994-1995, 2001-2002
- 1993 Task Force on Experiential Training for Doctor of Pharmacy Degree,  
College of Pharmacy, member

### **NATIONAL, REGIONAL, AND STATE PROFESSIONAL SERVICE**

1. **Arkansas Health Care Transparency Board**, Governor Appointed Member, 2016-present
2. **Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)**, Board Member, 2016-present
3. **Program Committee Co-Chair, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting.** May 21-25, 2016
4. **Reviewer, Academy of Managed Care Pharmacy (AMCP).** Abstract Reviewer, 2014 – present.
5. **Task Force Forum Presentation (ISPOR)**  
Johnson M, Beger M, Mamdani M, Crown W, Martin BC, Cox E. “Design and Analysis of Non-Randomized Studies of Treatment Effects Using Secondary Data. May 6, 2008. Toronto, Canada.
6. **International Society for Pharmacoeconomics and Outcomes Research (ISPOR)**  
Judge of Poster and Podium Presentations, 2002, 2004, 2005, 2010, 2013  
Abstract Review Committee, 2001-2003, 2005-present
7. **Southern Pharmacy Administration Regional Meeting**  
Abstract Review Chair, 2007  
Planning Committee Member, 2007
8. **Conference Advisory Committee**, Outcomes in Women’s Health Conference: Building Bridges Between Outcomes Research and Management of Women’s Health, April 16-18, 1998, Athens, GA.
9. **Reviewer**, American Pharmaceutical Association 1997 Annual Meeting

10. **Presider**, session entitled: "Research Issues Associated with Measuring Pharmaceutical Care Outcomes" at the Pharmaceutical Care Outcomes Research Conference: Linking Research to Practice. September 27, 1996, Athens, GA
11. **Conference Advisory Committee**, Pharmaceutical Care Outcomes Research Conference: Linking Research to Practice. September 26-28, 1996, Athens, G
12. **North East Georgia SAS Users Group Steering Committee, member**

## **CONSULTANTSHIPS**

Development and Validation of a Clinical Decision Support Tool to Guide Oral Anticoagulant Prescribing in Patients with Atrial Fibrillation. eMax Health and Daiichi Sankyo

Bleeding and Recurrent Venous Thromboembolism Risk. eMax Health and Daiichi Sankyo

Costs of Pulmonary Hypertension to Managed Care. Bayer Healthcare Pharmaceuticals in collaboration with Qayyim Said.

Development and Validation of an Economic Model to assess the cost of diabetes care in Florida Medicaid, University of Florida.

Prescription validation survey of electronic prescription records. Express Scripts, Inc.

Determining the Net Cost of IBS. Novartis, Inc.

Validation of a Disease Specific Quality of Life Instrument. Glaxo Inc.

Analysis of Migraine Productivity Work Losses. Glaxo Inc.

Economic Analysis of PRAISE. Pfizer Inc.

Development and Editorial Assistance of an Outcomes Research Guide Manual. Pfizer, Inc.